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aa      amino acid  
ATP      adenosine-5'-triphosphate  
BSA      bovine serum albumin  
BSE      bovine spongiform encephalopathy  
cAMP      cyclic adenosine monophosphate  
CC1      positively charged charge cluster of PrPC (aa 23-27)  
CC2      positively charged charge cluster of PrPC (aa 95-110)  
CD      central domain (of PrPC)  
CDP      chronic demyelinating polyneuropathy  
CJD      Creutzfeldt-Jakob disease  
CMT      Charcot-Marie-Tooth disease  
CNS      central nervous system  
Dpl      protein doppel 
Dhh      desert hedgehog  
DNA      deoxyribonucleic acid  
DRG      dorsal root ganglion  
EGFP      enhanced green fluorescent protein  
ELISA     enzyme-linked immunosorbent assay  
EM      electron microscopy  
Erk      extracellular-signal-regulated kinase  
FFI       fatal familial insomnia  
FT   flexible tail of referring to aa23-110 of the cellular PrP 
GDNF     glia cell line-derived neurotrophic factor  
GFP      green fluorescent protein  
GPI      glycosyl-phosphatidyl-inositol  
Gpr   G protein-coupled receptor 
Gpr126   G protein-coupled receptor 126 
GSS      Gerstmann-Sträussler-Scheinker syndrome  
HC      hydrophobic core (of PrPC)  
i.v.      intravenous  
kDa       kilo Dalton  
LPS      lipopolysaccharide  
MAG      myelin associated glycoprotein  
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MALDI-TOF/TOF  matrix-assisted laser desorption/ionization-tandem time-of-flight   
MAP      mitogen-activated protein  
MAPK     mitogen-activated protein kinase  
MBP      myelin basic protein  
MPZ       myelin protein zero (see also P0)  
NCV      nerve conduction velocity  
NGF      nerve growth factor  
NSE      neuron specific enolase  
OR      octarepeat region (of PrPC)  
PBS      phosphate-buffered saline  
PBST      phosphate-buffered saline (with) Tween-20  
PCR      polymerase chain reaction 
PIPLC   phosphatidylinositol-specific phospholipase C 
PK                    proteinase K  
P0      myelin protein zero (see also MPZ)  
PNS      peripheral nervous system  
PRNP      gene encoding the human prion protein  
Prnd    gene encoding the mouse doppel (doppelganger of the prion protein, Dpl)  
Prnp    gene encoding the mouse prion protein  
PrPC       cellular isoform of the prion protein  
PrPSc       pathological isoform of the prion protein  
RNA    ribonucleic acid  
RT      room temperature  
s.d.      standard deviation  
SDS-PAGE    sodium dodecyl sulphate polyacrylamide gel electrophoresis  
s.e.m      standard error of the mean  
Shh      sonic hedgehog  
SOD      superoxide dismutase  
TBST      tris-buffered saline (with) Tween-20  
TSE       transmissible spongiform encephalopathy  
wt      wildtype (mouse/ mice)
THE ROLE OF AXONAL PRION PROTEIN IN MYELIN MAINTENANCE 
9 
 
Parts of the Summary, Introduction, Results, Methods and Discussion sections are reproduced or adapted 
from our following publication: 
 
“The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6.”  
By Alexander Küffer, Asvin K K Lakkaraju, Amit Mogha, Sarah C Petersen, Kristina Airich, Cédric 
Doucerain, Rajlakshmi Marpakwar, Pamela Bakirci, Assunta Senatore, Arnaud Monnard, Carmen 
Schiavi, Mario Nuvolone, Bianka Grosshans, Simone Hornemann, Frederic Bassilana, Kelly R Monk 
and Adriano Aguzzi 
 
published in Nature August 25th 2016, issue 536, page 464-468. 
 
 




Ablation of the cellular prion protein PrPC leads to a chronic demyelinating polyneuropathy (CDP) 
affecting Schwann cells. Neuron-restricted PrPC expression prevents the disease (Bremer et al., 2010b), 
suggesting that it acts through an unidentified Schwann cell receptor. In my thesis I found that the 
cAMP concentration in PrPC deficient sciatic nerves is reduced, suggesting the involvement of a G 
protein-coupled receptor GPCR. The amino-terminal "flexible tail" FT (residues 23-120 of PrPC) 
triggered a concentration-dependent cAMP increase in primary Schwann cells, in the Schwann-cell line 
SW10, and in Hek293T cells overexpressing the GPCR Gpr126/Adgrg6. In contrast, naïve Hek293T 
cells and Hek293T cells expressing several other GPCRs did not react to the FT and ablation of Gpr126 
from SW10 cells abolished the FT-induced cAMP response. The FT contains a polycationic cluster 
(KKRPKPG) similar to the GPRGKPG motif of the Gpr126 agonist, type-IV collagen Col 4 (Paavola 
et al., 2014). A KKRPKPG-containing PrPC-derived peptide (FT23-50) sufficed to induce a Gpr126-
dependent cAMP response in cells and mice and improved myelination in hypomorphic Gpr126 
zebrafish mutants. Substitution of the cationic residues with alanines abolished the biological activity 
of both FT23-50 and the respective Col4 peptide. I conclude that PrPC promotes myelin homeostasis 
through FT-mediated Gpr126 agonism. Besides clarifying the physiological role of PrPC, these 
observations may be relevant to the pathogenesis of demyelinating polyneuropathies, common 
debilitating diseases with limited therapeutic options.  
  




Die Ablation des zellulären Prionproteins PrPC führt zu einer chronischen demyelinisierenden 
Polyneuropathie CDP. Auf Neuronen beschränkte PrPC-Expression verhindert die Krankheit (Bremer 
et al., 2010b), was darauf hindeutet, dass PrPC via einen bisher nicht identifizierten Schwann-
Zellrezeptor zu Myelinisierung führt. Ich habe in meiner Dissertation  herausgefunden, dass die cAMP-
Konzentration in PrPC-defizienten Ischiasnerven reduziert ist, was auf die Beteiligung eines G-Protein-
gekoppelten Rezeptors (GPCR) schließen lässt. Der aminoterminale flexible Teil (FT, Reste 23-120) 
von PrPC löste einen konzentrationsabhängigen cAMP-Anstieg in primären Schwann-Zellen, in der 
Schwann-Zelllinie SW10 und in Gpr126/Adgrg6 überexprimierenden Hek293T-Zellen aus. Im 
Gegensatz dazu reagierten naive Hek293T-Zellen und Hek293T-Zellen, die mehrere andere GPCRs 
exprimierten, nicht auf FT und die Ablation von Gpr126 aus SW10-Zellen hob die FT-induzierte 
cAMP-Antwort auf. FT enthält einen polykationischen Cluster (KKRPKPG), der dem GPRGKPG-
Motiv des Gpr126-Agonisten Typ IV-Collagen Col4 ähnlich ist (Paavola et al., 2014). Ein KKRPKPG-
haltiges, von PrPC abgeleitetes Peptid (FT23-50) reichte aus, um eine Gpr126-abhängige cAMP-Antwort 
in Zellen und Mäusen zu induzieren und verbesserte die Myelinisierung in hypomorphen Gpr126-
Zebrafischmutanten. Die Substitution der kationischen Reste durch Alanine hob die biologische 
Aktivität sowohl von FT23-50 als auch des jeweiligen Col4-Peptids auf. Ich schließe daraus, dass PrPC 
die Myelinhomöostase durch FT-vermittelten Gpr126-Agonismus fördert. Neben der Aufklärung der 
physiologischen Rolle von PrPC können diese Beobachtungen auch für die Pathogenese von 
demyelinisierenden Polyneuropathien relevant sein.  




4.1 The cellular prion protein 
4.1.1 PrPC 
The PRNP gene in humans and the Prnp gene in mice encode the cellular prion protein PrPC, a 35kD 
glycosylphosphatidylinositol-anchored and membrane bound extracellular protein with 2 N-linked 
glycosylation sites. Its secondary structure is described as a carboxy-terminal globular domain (aa135-
231) formed by three α-helices and two β-sheets. The amino-terminal domain aa 23-110 is called the 
“flexible tail” FT, because NMR-Spectroscopy analysis revealed no distinct secondary structure (Riek 
et al., 1996). The hydrophobic core HC (aa111-134) connects the globular domain and FT. FT contains 
two charge clusters CC1(23-27) and CC2(95-110) and the octapeptide repeat region OR.  
 
Figure 4.1. The cellular prion protein. Adapted from (Aguzzi et al., 2008), SP signaling peptide, CC1/CC2 charge clusters 
1 and 2, OR octapeptide repeats, HC hydrophobic core, H1-3 α-helices, GPI glycosylphosphatidylinositol anchor. 
 
4.1.2 PrPC is GPI-anchored 
After translation and transport to the cell surface, PrPC is assigned to extracellular lipid rafts (Naslavsky 
et al., 1997). 70-80% of PrPC has been reported to be released from the cell surface of N2a cells stably 
transfected with chicken Prnp after phosphatidylinositol-specific phospholipase C (PIPLC) treatment 
(Harris et al., 1993), indicating that PrPC is anchored to the extracellular membrane by a GPI-anchor. 
Full length PrP is also physiologically shedded at the GPI-anchor, releasing the entire protein in a 
soluble form. Interestingly, membrane anchorage seems to be a prerequisite for α-cleavage, since PrP 
mutants lacking a GPI anchor are not proteolytically processed at the α-site.  
4.1.3 Posttranslational proteolytic processing of PrP 
PrPC can undergo α-, b- and probably g-cleavage events. The first description of PrPC α-cleavage was 
published by Harris et al. (Harris et al., 1993) who studied posttranslational processing and trafficking 
in chicken PrPC. They found that stably transfected A26 cells released a 11.5kD fragment into culture 
media. Immunoblotting with different antisera revealed a peptide starting at the very amino-terminus 
of PrPC, just after the signal sequence at Lys25 (chicken numbering) up to a cleavage site around Phe116. 
More than half of PrPC was N-terminally truncated, indicating the importance of this event under 
physiological conditions. α-cleavage in mice occurs at around aa110/111 resulting in the membrane 
bound carboxy-terminal C1 fragment (aa111-231) and the soluble amino-terminal N1 fragment also 
called FT(aa23-110) (Chen et al., 1995; Mange et al., 2004). α-cleavage is an important process since 
it can prevent the C1 fragment from being misfolded into PrpSc (Westergard et al., 2011). Transgenic 
mice expressing mutant forms of PrPC which did not undergo physiological α-cleavage, suffer from 
neurodegeneration and polyneuropathy suggesting that α-cleavage is crucial for physiological function 
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of PrPC. ADAM family metalloproteinases have been reported to cleave PrPC (Altmeppen et al., 2015). 
Different mutant forms of PrPC with alterations around the α-cleavage site revealed a surprisingly 
limited sequence specificity for cleavage (Oliveira-Martins et al., 2010). b-cleavage is leading to the 
fragments N2 and C2. It is mainly a pathological process since C2 is protease resistant and detergent-
insoluble. C2 fragment is abundant in CJD brains (Chen et al., 1995). g-cleavage was recently 
discovered generating a C3 fragment of which the function is still unclear (Lewis et al., 2016). 
4.2 Scrapie prion protein PrPSc 
Scrapie prion protein PrPSc is the disease-associated isoform of PrPC, which is post-translationally 
modified and comprises increased β-sheet content. PrPSc is insoluble in non-denaturating agents and 
shows partial protease resistance (Prusiner, 1982). PrPSc is differently cleaved by the so called β-
cleavage event.  
4.3 The aminoterminus of PrPC in disease 
When looking for polymorphisms and mutations in the PRNP gene, it is very obvious that a vast 
majority affects the carboxy-terminal part of the protein. Only a handful of polymorphisms and 
mutations are reported in the aminoterminus. This shows that mutations in the amino terminus of PRNP 
are hardly tolerated. A loss of function of the probably important amino terminus seems to have an 
evolutionary negative effect and has been selected out. A Pro to Leu point mutation at codon 102 with 
methionine homozygosity at codon 129 was reported in a 54 year old Japanese woman suffering from 
Gerstmann-Sträussler-Scheinker GSS like symptoms such as dementia, gait disturbance myoclonic and 
akinetic mutism (Iwasaki et al., 2014). A similar disease with a slower course occurred in a 57 year old 
Japanese woman and a P105L mutation in PRNP was diagnosed (Yamazaki et al., 1999). The missense 
P39L variant was the cause of a case of frontotemporal dementia FTD in a 67 year-old male with short 
term memory deficit, postural deficit and positive family history for dementia (Oldoni et al., 2016). 
And the same P39L mutation was reported in two further FTD cases in Italy (Bernardi et al., 2014). A 
Chinese group studied PRNP gene mutations in a huge population of 683 patients with either 
Alzheimer’s disease or frontotemporal dementia FTD and detected a novel S17G missense mutation in 
a 70 year-old female patient suffering from Alzheimer’s disease (Zhang et al., 2016). The mutation 
S17G affects the signaling peptide important for PrP trafficking and is not part of PrP itself. Individuals 
with 10 or more octapeptide repeats develop a transmissible familial Creutzfeldt-Jakob disease 
(Goldfarb et al., 1991). On the other hand, a two-octapeptide repeat deletion was found in a patient with 
rapidly progressing dementia (Beck et al., 2001). The number of octapeptide repeats is negatively 
proportional to patient age at disease onset.  
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4.4 Function of the prion protein 
4.4.1 Generation of prion protein deficient mice 
By the end of the 1980s the generation of knock out mice became feasible (Mansour et al., 1988) and 
already in 1992 the first Prnp-/- mouse has been created. PrPC is expressed in most tissues and highly in 
CNS and peripheral nerves (Bendheim et al., 1992), therefore an obvious phenotype of a knock out 
mouse was expected. But the Prnp-/- mice were viable, fertile and showed a normal life expectancy. 
Therefore, they were considered as healthy throughout. Most surprisingly, Prnp-/- mice were even 
resistant to prion infection (Bueler et al., 1993; Sailer et al., 1994). The only identified function of the 
prion protein was causing vulnerability for prion’s disease. Later on, when transcriptomics got 
available, the expression of PrPC during CNS development was studied in more detail. Interestingly, 
the number of differentially expressed genes in the hippocampus of PrPC-deficient mice compared to 
wild-type animals was low (Benvegnù et al., 2011). There was no obvious difference even in strictly 
co-isogenic ZH3 mice (Nuvolone et al., 2016), concluding that lack of PrPC can be compensated during 
CNS development. However, a bigger difference occurs when PrPC is deleted postnatally when 
compensation for gene loss is not easily done anymore (Chadi et al., 2010).  
4.4.2 Doppel overexpression 
In 1996, a phenotype with ataxia and loss of cerebellar Purkinje neurons was reported (Sakaguchi et al., 
1996). The problem occurred in four Prnp-/- lines caused by a targeting vector design resulting in a 
larger deletion of Prnp exon 3 containing a splice acceptor site. This resulted in overexpression of the 
Prnd gene and its gene product the Doppel protein (Moore et al., 1999)and therefore the symptoms 
were not caused by Prnp ablation. 
4.4.3 Genetic challenges with Prnp ablation 
To create the very first Prnp-/- mouse strain ZH1, a mixed C57BL/6 J × 129/Sv(ev) background was 
used. The knockout alleles have been generated in Sv129 embryonic stem cells and resulting mice were 
backcrossed for more than 12 generations on a black 6 strain. Even after 12 generations of  
backcrossing, a tiny part of the chromosome flanking the Prnp locus originates from the Sv129 mouse 
strain. Some functions attributed to PrPC  were in reality caused by polymorphisms in a flanking gene 
and were not a function of PrPC (Bueler et al., 1993). The best studied example is the role of PrPC in 
phagocytosis. Macrophages of Prnp-/- mice were reported to present superior phagocytic activity 
leading to the hypothesis that PrPC negatively regulates phagocytosis (de Almeida et al., 2005). 
Expression of PrPC in macrophages is very low and therefore some doubt was raised against this finding. 
In our lab, we could show that polymorphisms in the Prnp-flanking gene SIRPa were responsible for 
alterations in phagocytosis of apoptotic cells (Nuvolone et al., 2013). In 2014 a new Prnp-/- mouse was 
created with TALEN nucleases in fertilized mouse oocytes (Nuvolone et al., 2016). The genetic 
background was kept strictly black six. These mice have been called Zurich 3 (ZH3) and they differ 
from wild-type mice only by deletion of 8 nucleotides resulting in disruption of the PrP reading frame. 
Consistently, all studies that do not use the ZH3 mouse or the Edinburgh Mouse should be repeated 
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with one of these mouse strains. Since the ZH3 mouse only existed from 2014 onwards, most of the 
studies about the function of PrPC were performed in non-coisogenic mouse strains. All these studies 
should be interpreted with particular caution. 
4.4.4 Deletion variants of the flexible tail FT(23-110) 
To identify the domain causing the isoform switch from PrPC to PrPSc, transgenic mice expressing 
truncated prion proteins have been generated. Surprisingly, expression of only part of PrP caused 
spontaneous neurodegenerative disease and co-expression of full length PrP could again rescue the 
neurotoxic phenotype. First deletion mutants of the flexible tail were published by Fischer who re-
introduced full length PrPC or PrP lacking the 26 and 46 very amino-terminal amino acids into Prnp-/- 
mice (Fischer et al., 1996). Mice were then infected with prions and all of them accumulated PrPSc and 
died from fatal neurodegeneration leading to the conclusion that the aminoterminus of PrPC plays no 
role in conformational change from PrPC to PrPSc. In 1997 Muramoto et al. deleted aa 23-88 which 
contains charge cluster 1. These mice were healthy and could be infected with PrPSc (Muramoto et al., 
1997). Charge cluster 2 around aa100 might replace the function of CC1 in those mice. But deletions 
including CC2, PrPΔ23−88 Δ95−107 showed no phenotype either and propagated PrPSc. Shmerling 
created further deletions of aa 32-121 and aa 32-134. These mice unexpectedly developed ataxia and 
degeneration of the cerebellar granular layer 2-3 month after birth. The phenotype could be rescued by 
reintroduction of a wt Prnp gene. Shorter deletions aa 32–80, 32–93 or 32–106 did not lead to 
spontaneous neurodegeneration. Shmerling hypothesized that truncated PrP variants may compete with 
similar proteins for a common ligand (Shmerling et al., 1998).  
4.4.5 Prion protein knockout animals 
The cellular prion protein has been ablated in cattle (Richt et al., 2007) and goats (Yu et al., 2006) and 
there is one published report about a spontaneous mutation leading to naturally prion protein ablated 
Norwegian dairy goats. All these animals are healthy, but they have not been thoroughly examined and 
there is no interest of the companies involved to do so. At the beginning of my work with peripheral 
nerves, I asked a company generating prion protein knockout cows if I could get peripheral nerve tissue. 
Unfortunately, I have never received an answer to my request. The knockout cows were generated with 
the aim of raising cattle for the food market. Had w found a pathology in these animals, this would have 
put the company's business at risk. 
4.4.6 PRNP deficiency in humans 
In a large population analysis containing exome sequencing data of over 76000 individuals, three 
heterozygous loss-of function variants were identified (Minikel et al., 2016). A PRNP-/- human is not 
reported so far.  
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4.4.7 Sleep regulation 
Mutations in the PRNP gene are responsible for the development of fatal familial insomnia FFI, so it is 
not surprising that a role of PrPC in the regulation of circadian rhythm was suspected. Indeed ZH1 and 
Edinburgh Prnp-/- mice showed altered activity patterns in changing light/dark cycles and sleep was 
more fragmented compared to wild-type controls (Tobler et al., 1996). Prnp-/- mice have an increased 
slow wave activity (SWA) after severe sleep deprivation (Huber et al., 1999). 
4.4.8 PrPC and memory 
Synaptic dysfunction or even synaptic loss is an early change in prion’s disease (Jeffrey et al., 2000) 
Following prion infection by injecting the mouse scrapie strain 22L, pre-and postsynaptic degeneration 
were predominantly detected in the stratum radiatum of the hippocampus (Šišková et al., 2013). After 
synaptosomal fractionation, PrPC was isolated from synaptic membranes and synaptic activity 
correlated with the amount of PrPC in presynaptic neurons in cerebellar slices (Herms et al., 1999). ZH1 
and Edbg mice showed weakened GABA receptor-mediated fast inhibition (Collinge et al., 1994) and 
impaired long-term potentiation (Manson et al., 1995). The neurophysiological phenotype with 
weakened inhibitory GABAergic synaptic transmission and impaired long-term potentiation could be 
rescued by introduction of human PrPC in high copy numbers and seemed to be specific (Whittington 
et al., 1995). But shortly after, contradictory studies were published. According to them, Prnp-/- mice 
had no deficit in synaptic inhibition and did not show any difference in long-term potentiation (Lledo 
et al., 1996). The first report by Büeler et al. did not mention any significant differences in memory 
performance, although Prnp-/- mice were searching a bit longer for a submerged platform in the swim 
test, what was interpreted as superior spatial memory or reduced behavioral flexibility (Bueler et al., 
1992). A later study showed impaired spatial learning with normal non-spatial learning and a reduction 
in long-term potentiation. These deficiencies were cell-type specific for neurons since reintroduction of 
PrPC under the neuron-specific enolase promotor (NSE) fully rescued the condition (Criado et al., 2005). 
Memory disturbances were reported to be age dependent (Coitinho et al., 2003) with differences in 9-
month old animals. On the other hand a 2-year longitudinal study revealed no deficiencies in spatial 
learning (Lipp et al., 1998). 
4.4.9 Copper, zinc and lactate metabolism 
In 1965, William Carlton treated mice with the copper chelator Cuprizone aiming to create a mouse 
model to study the known neurodegeneration triggered by copper deficiency. The common histological 
features of copper deficiency and scrapie disease with spongiform change and severe demyelination of 
cerebellum and brainstem were discussed again in 1971. Thanks to the phenocopy of the diseases, it 
was hoped to gain an insight into the underlying pathophysiology. Re-substitution of copper could not 
rescue the demyelinating effect of copper chelation and  it remained unclear if cuprizone exerts a direct 
toxic effect on myelin. 20 years later, Brown described 5 to 6 copper binding sites in the octapeptide 
repeat domain PHGGGWGQ of PrPC. Two different Prnp-/- mouse lines (ZHI and Edinburgh) showed 
reduced copper contents in membrane enriched brain extracts and in synaptosomal and endosomal 
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enriched fractions (Brown et al., 1997). Although copper contents are altered in Prnp-/- mice they do 
not show any of the severe symptoms of a disturbed copper homeostasis.  Binding to the histidine 
residues of the octapeptide repeats was reported to be specific for Cu2+ (Stöckel et al., 1998) but the 
octapeptide repeat domain is also involved in zinc uptake (Watt et al., 2012). Maybe any divalent cation 
is able to interact with the OR. Copper causes a conformational change in the amino-terminus(Viles et 
al., 1999), therefore a functional change of PrPC upon copper binding is feasible. Copper can induce 
PrPC expression in primary hippocampal and cortical neurons (Varela-Nallar et al., 2006). A recent 
structural study reported an interaction of the copper bound octapeptide repeat domain with a charged 
c-terminal pocket in the globular domain which matches exactly the POM1 antibody recognition 
site(Evans et al., 2016). POM 1treatment is toxic in cerebellar slice cultures and the flexible tail is 
needed to transduce toxic signaling originating in the globular domain (Sonati et al., 2013). The authors 
propose an important role in the regulation of the flexible N-terminus of PrPC. Copper seems not to play 
an important role in prion infection since mice lacking the effector site for copper binding, the 
octapeptide repeat domain, are still susceptible to scrapie. Interestingly, these mice still have a lower 
incubation time and histopathologic changes in the brain are absent while they are unchanged in the 
spinal cord (Flechsig et al., 2000). PrPC is also reported to be involved in the regulation of lactate 
transport in astrocytes mediated by its interaction with GluR2-containing AMPA receptors. 
4.4.10 PrPC and metabotropic glutamate receptors 
PrPC interacts with two metabotropic glutamate receptors of group I, mGluR1 and mGluR5, which are 
G protein-coupled receptors. Both receptors are normally activated by Glutamate but PrPC can bind to 
mGluR5 in a complex with Ab-oligomers, leading to intracellular Fyn activation (Um et al., 2013). Aβ–
PrPC–mGluR5-complexes can lead to long-term depression in vivo (Hu et al., 2014) and loss of 
dendritic spines in neuronal cultures (Um and Strittmatter, 2013). Coworkers in our lab, Goniotaki et 
al. found a delayed onset of motor deficits and a prolonged survival in prion infected mice treated with 
the mGluR5 inhibitor MPEP, showing that mGluR1 and mGluR5 can form toxic complexes with PrPC 
(Goniotaki et al., 2017). Again these functions of PrPC occur under pathologic conditions and do not 
give a hint about the physiological function of PrPC. Therefore the study of Beraldo has to be mentioned 
which reports a signaling pathway for neuritogenesis initiated by PrPC and laminin complexes via 
metabotropic glutamate receptors of group I (Beraldo et al., 2010).  
4.4.11 Oxidative stress and superoxide dismutase activity 
Superoxide dismutase activity is diminished in brain und muscle of Prnp-/- mice (Klamt et al., 2001). 
Waggoner et al. could not confirm the finding for Cu-Zn superoxide dismutase and cytochrome C 
expression levels in brain extracts, as those were similar in Prnp-/- mice compared to controls 
(Waggoner et al., 2000). Furthermore, our own group could not find a contribution of PrPC to total SOD 
activity (Hutter et al., 2003).  




Interestingly the mitochondria number in CA1 hippocampal neurons and in the myocardium of 
Edinburgh Prnp-/- mice is reduced (Miele et al., 2002) but a study measuring mitochondrial respiration 
in different regions of Prnp-/- brains revealed no change compared to controls (Lobão-Soares et al., 
2005). 
4.4.13 Phagocytosis and immune response 
Macrophages of Prnp-/- mice were reported to present superior phagocytic activity culminating in the 
hypothesis that PrPC negatively regulates phagocytosis (de Almeida et al., 2005). In fact, PrPC 
expression in macrophages is very low and the finding was caused by a flanking gene bias (Nuvolone 
et al., 2013). Prnp-/- mice better tolerate infection with the bacterium Brucella abortus (Watarai et al., 
2003). This data could not be reproduced in B. suis (Fontes et al., 2005). Prnp-/- mice are even refractory 
to infection with herpes simplex virus (Thackray and Bujdoso, 2002) a finding which seems more 
plausible since PrPC overexpressing tga20 mice were easily infected by herpes simplex virus. An 
advantage against Brucella or Herpes simplex virus infection would have been an evolutionary 
advantage for Prnp null alleles which are very rare and were obviously not selected (Aguzzi and Hardt, 
2003). But one has to admit that also prion’s disease did not elicit selective pressure in favor of the 
Prnp null allel and therefore it’s plausible that PrPC indeed has an important function. Otherwise it’s 
hard to argue why this protein is highly conserved in vertebrates. PrPC on dendritic cells were reported 
to be crucial for T-cell stimulation in vitro and in vivo (Ballerini et al., 2006). 
4.4.14 Neuronal excitability and seizures 
CA1 hippocampal neurons from ZH1 Prnp-/- mice presented faster after-hyperpolarization currents and 
impaired long term potentiation (Collinge et al., 1994). Similar findings were described in Edinburgh 
Prnp-/- mice by Manson (Manson et al., 1995). Reintroduction of PrPC could rescue the phenotype 
(Whittington et al., 1995). Other groups could not reproduce the findings (Herms et al., 1995; Lledo et 
al., 1996) but published contradictory data in a later study (Herms et al., 2001). ZH1 Prnp-/- mice are 
prone to seizures upon injection of kainic acid, a finding reproduced independently by two different 
groups (Rangel et al., 2007; Walz et al., 1999). Timm staining of the hippocampus showed more 
granules in the granular layer, the inner molecular layer of the dentate gyrus and the infrapyramidal 
region of CA3 (Colling et al., 1997). 
4.4.15 Chronic demyelinating neuropathy in Prnp-/- mice 
Our group reported an extensive chronic demyelinating polyneuropathy CDP in four independent Prnp-
/- mouse strains at 60 weeks of age (Bremer et al., 2010a). The CDP was evident in all examined 
peripheral nerves, including sciatic and trigeminal nerves. Genetic reintroduction of PrPC via crosses to 
the PrP overexpressing tga20 mice, or introduction of one Prnp allele fully prevented the 
polyneuropathy. Electron microscopic analysis of 60 week old Prnp-/- mice showed characteristic 
ultrastructural signs of demyelination. Electrophysiological analyses performed on sciatic nerves 
revealed significantly reduced nerve conduction velocities in Prnp-/- mice. Our group further showed 
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that Prnp-/- mice expressing the tgNSE-Prp transgene which expresses PrPC specifically in neurons 
(Radovanovic et al., 2005) did not suffer from polyneuropathy (Bremer et al., 2010a), leading us to the 
unexpected conclusion that neuronal expression of PrPC is required for myelin sheath maintenance. The 
proteolytic α-cleavage event seems to be important to prevent peripheral neuropathy. PrP in tgC4 mice 
(Δ32-93) and tgPrPΔCC mice (Δ94-110) are α-cleaved and mice do not show peripheral neuropathy. On 
the other hand, tgE11 (Δ32-121) and tgF35 (Δ32-134) suffer from peripheral neuropathy and these 
deletion variants are not cleaved and the probable signaling domain aa 23-32 is retained at the cell 
surface. E11 and F35 mice do not have a normal life expectancy and they suffer from cerebellar 
degeneration indicating a deleterious effect if cleavage cannot happen.  This is also the case in deletions 
of the hydrophobic core HC tgPrPΔHC (Δ111-134) that show no cleavage and therefore neuropathy.  
4.5 Myelination 
Myelin is formed by Schwann cells in the peripheral nervous system PNS or by oligodendrocytes in the 
central nervous system CNS. Myelin contains 40% water and 60 % solid mass of which around 2/3 are 
lipids and 1/3 are proteins. The high lipid content was leading to the name “white matter” for the 
myelinated substance in the CNS. Ensheathing axons with myelin enhances the conduction of nerve 
impulses and enables saltatory conduction which makes signal propagation up to 100 times faster 
(Tasaki, 1939). Myelin wrapping protects the axon and glia cells play a crucial role in maintaining 
neuronal homeostasis. Schwann cells regulate the molecular domains of myelinated axons and rule the 
diameter of axons (Salzer et al., 2008). Some authors see an advantage in energy saving since action 
potentials in myelinated axons do not occur along the entire axon but are focused to the internodes 
(Wang et al., 2008). But this will not be outweighing the expenses for the generation of glia. 
Remyelination occurs in the CNS and PNS after damage. Interestingly, Schwann cells and 
oligodendrocyte precursor cells OPCs recapitulate signaling cascades active in development during 
repair (Franklin and Ffrench-Constant, 2008).  
4.5.1 Development of Schwann cells 
Schwann cells are derived from neural crest cells which develop to Schwann cell precursors SCPs. 
SCPs develop in mice at E12-13 and progress to immature Schwann cells at E13-15 (Jessen and Mirsky, 
2005). If an immature Schwann cell can randomly associate with a large diameter axon, it upregulates 
myelin signaling and will become a mature myelinating Schwann cell. Other immature Schwann cells 
not undergoing radial sorting develop into mature non-myelinating Schwann cells. The transcription 
factor Sox10 is required for glial development and it is expressed by all neural crest cells. In mice 
deficient of Sox10, SCPs are missing but neurons are initially present in normal numbers. (Britsch et 
al., 2001). Sox10 regulates the expression of the neuregulin1 receptor ErbB3 and therefore enables the 
axon to glia signaling of Nrg1. In the PNS, neuregulins are the most important regulators of Schwann 
cell development (Birchmeier and Nave, 2008). The most important neuregulin gene is NRG1. NRG1 
type III is expressed on the axonal membrane and determines if an axon will be myelinated (Taveggia 
THE ROLE OF AXONAL PRION PROTEIN IN MYELIN MAINTENANCE 
20 
 
et al., 2005) and it dictates the diameter of the myelin sheeth (Michailov et al., 2004). Nrg1 enables the 
migration of neural crest cells to the ventral location of sympathetic gangliogenesis (Britsch et al., 
1998). Nrg1 regulates survival, maturation and proliferation of Schwann cell precursors (Dong et al., 
1995). Cooperatively with Nrg1, expression of Notch stimulates the formation of mature Schwann cells 
out of SCPs and suppresses neuronal development in neural crest cells, while it enforces the glial lineage 
(Morrison et al., 2000). On the other hand, Bmp2 and Bmp4 are important blockers of glial 
differentiation from neural crest cells (Shah et al., 1996). Schwann cell precursors convert to immature 
Schwann cells at E13-15 in mice. Simultanously, the perineurium is formed and the nerves start to 
become vascularized. Immature Schwann cells are in contrast to SCPs able to maintain survival 
signaling in a autocrine fashion. Therefore, the molecular expression pattern changes and factors such 
as insulin-like growth factor 2 IGF2, platelet-derived growth factor-b PDGFB, leukemia inhibitory 
factor LIF and lysophosphatidic acid LPA get upregulated. Immature Schwann cells express the 
transcription factors Sox2, Brn2 and Oct6 and get in contact to axons in a 1:1 ratio during the process 
of radial sorting. If axonal contact is established, Oct6 induces expression of transcription factor Krox 
20/Egr2, which is upregulated just before myelination in mature Schwann cells happens (Topilko et al., 
1994).With further contact to the basal lamina, an expression pattern of mature Schwann cells is 
achieved and proteins such as GFAP, S-100, desert hedgehog dhh and  finally the myelin proteins PMP-
22, PLP and P0 are expressed. 
4.5.2 G protein coupled-receptors in PNS myelination 
The G protein-coupled superfamily of receptors represent the largest group of membrane receptors and 
they are very well known as the most druggable receptor class since the majority of pharmacological 
agents work via GPCRs. The role of adhesion Gpr126/Adgrg6 in PNS myelination has been identified 
in a genetic Zebrafish screen (Pogoda et al., 2006), see further discussion below. Interestingly, cAMP 
is highly elevated after Gpr126 activation (Mogha et al., 2013). As mentioned above, axonal neuregulin 
1 type III is most important for Schwann cell differentiation. Nrg1 type III is cleaved extracellularly 
which results in the induction of prostaglandin D2 synthase PGDS. PGDS then catalyzes the generation 
of prostaglandin D2 PGD2 which is a ligand of Gpr44. PGD2 binds to Gpr44 on the Schwann cell 
membrane, Grp44 gets activated and dephosphorylates the transcription factor NFATc4, which can 
translocate into the nucleus and activate promyelinating signals (Kao et al., 2009; Trimarco et al., 2014). 
LPA1 is a GPCR present on Schwann cells. It is activated by its ligand lysophosphatidic acid LPA 
which is an important survival factor for Schwann cells produced by neurons (Weiner and the of 
Sciences, 1999). Mutations in Gpr56/Adgrg1 have been reported to cause polymicrogyria in the 
neocortex. Gpr56 regulates radial sorting in early Schwann cell development through RhoA signaling 
(Ackerman et al., 2018). 




4.6.1 Adhesion G protein-coupled receptors 
Adhesion GPCRs combine the function of a GPCR with characteristics of adhesion molecules. Similar 
to other GPCRs, adhesion GPCRs consist of a seven-transmembrane (7TM) heptahelical domain and 
an intracellular domain which couples to the heterotrimeric G-proteins. A special feature of aGPCRs is 
the long amino-terminal extracellular domain (ECD) containing cell-cell adhesion motifs leading to the 
name “adhesion” GPCR. Many aGPCRs have the ability to cleave themselves into an amino-terminal 
(NTF) and a caboxy-terminal fragment (CTF). This cleavage occurs at the GPCR autoproteolysis 
inducing GAIN domain which contains the highly conserved GPCR proteolysis site GPS.   
4.6.2 Adhesion GPCRs in neurological disease 
Single nucleotide polymorphisms SNPs in BAI3/ADGRB3 have been identified in Schizophrenia 
patients (DeRosse et al., 2008).  CELSR1/ADGRC1 mutations are associated with severe neural tube 
defects such as spina bifida (Allache et al., 2012; Lei et al., 2014; Robinson et al., 2012). SNPs in 
LPHN3/ADGRL3 are found in individuals with attention deficit hyperactivity disorder ADHD (Arcos-
Burgos et al., 2010; Lange et al., 2012; Ribases et al., 2011). Gpr98 /ADGRV1 is involved in Usher 
Syndrome Type II (Weston et al., 2004). Gpr56 regulates cortical development and lamination via 
binding to collagen III (Luo et al., 2011). 
4.6.3 Discovery and cloning of Gpr126  
In 2003 Frederiksson et al. reported six novel GPCRs, Gpr123-128, found in a BLAST search in the 
Celera database using known long-N-termini of GPCRs as a bait (Fredriksson et al., 2003). GPR126 
was identified having a GPS domain in the N-terminus and a Ser/Thr rich region. Stehlik et al. cloned 
GPR126 from human umbilical vein endothelial cells where it is highly expressed and they called it 
vascular inducible GPCR (VIGR) because its expression could be induced by treatment of human 
umbilical vein endothelial cells HUVEC with lipopolysaccharides LPS or thrombin (Stehlik et al., 
2004). 
4.6.4 GPR126 in angiogenesis 
Gpr126 is highly expressed in endothelial cells as well as embryonic stem cells expressing vascular 
endothelial growth factor receptor 2 VEGF2 (Cui et al., 2014). Cui et al. isolated Flk1/Vegfr2-positive 
cells at day 4 of embryoid body formation and screened for the expression of 100 orphan GPCRs. 
Gpr126 mRNA showed a similar expression profile like VEGFR2. Knockdown of Gpr126 in the mouse 
retina resulted in inhibition of hypoxia induced angiogenesis. Defects in intersegmental vessel 
formation were found in zebrafish after treatment with Gpr126 specific morpholinos. GPR126 
activation is leading to cAMP induced GATA2 and STAT5 expression. 
4.6.5 Gpr126 in heart development 
Waller-Evans et al. created targeted mutations in which the sequence encoding part of the 7TM region 
is deleted and a LacZ reporter gene cassette is inserted into the 7TM locus. Homozygous mice are 
embryonically lethal, at dpf 13,5 no viable homozygous offspring is left (Waller-Evans et al., 2010). 
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Dead embryos showed signs of cardiac failure such as edema, congestion and internal hemorrhage. 
Trabeculation of the ventricular wall is normal at dpf 10,5 and they could not identify any reduction of 
myocardium or trabeculation. On the other hand, embryos dissected after cardiac failure has happened, 
showed a thinning of the myocardial wall. Later on, Patra et al. studied heart development in Zebrafish 
(Patra et al., 2013). Cardiac trabeculation was inhibited at 80 hpf in Gpr126 depleted animals. When 
they used morpholinos targeting the NTF of GPR126 without the GPS domain, no cardiac phenotypes 
were observed. Mitochondria in Gpr126 depleted zebrafish remained without any abnormalities. Then 
they studied Riken-Gpr126-/- mice, which suffer from bradycardia, cardiac arrhythmia, thinner 
ventricular walls and lesser trabecula. Mitochondria in cardiomyocytes presented structural alterations 
such as complex shape, less well developed cristae and electron-dense precipitates. Gpr126-/- 
mitochondria had more lipid droplets and lesser glycogen deposits than wt mitochondria. Patra et al. 
conclude that the contractility phenotype of GPR126-/- mice is caused by defective mitochondria. A 
metabolic shift from fatty acid oxidation to glycolysis results in lipid accumulation. Gpr126 depleted 
zebrafish do not show any mitochondrial alterations, because heart morphogenesis in zebrafish relies 
more on glycolysis than fatty acid oxidation. Furthermore, the cardiac phenotype could be rescued by 
co-injection of a Gpr126-NTFdelGPS construct, indicating that Gpr126-NTF signaling is crucial for 
heart morphogenesis. 
4.6.6 Gpr126 in inner ear development 
During formation of the semicircular canals of the inner ear in zebrafish, epithelial projection outgrowth 
is promoted by expression of extracellular matrix ECM protein expression. The semicircular ducts fuse 
with the otic vesicles and form pillars. If the Gpr126 gene is disrupted, the so called “lauscher” mutants 
fail to fuse semicircular canals with the otic vesicle and do not downregulate ECM protein expression 
resulting in a swelling of the inner ear. The hypomorphic lauscher phenotype can be partially rescued 
by cAMP agonists indicating that Gpr126 functions via Gs signaling during inner ear development. 
Four Gs proteins are known in Zebrafish. Sequencing of lauscher mutant cDNA revealed two missense 
mutations in the fourth transmembane domain (I963N; P969L) and two nonsense mutations causing 
truncated receptors L463X and W804X (part of GPS motif) (Geng et al., 2013). 
4.6.7 Gpr126 in disease 
Kou et al. performed a genome wide association study GWAS in 1819 patients with adolescent idiopatic 
scoliosis AIS and identified a susceptibility locus on chromosome 6q24.1. The most significantly 
associated SNPs were identified in the Gpr126 gene (Kou et al., 2013). When Gpr126 is deleted in 
osteochondroprogenitor cells using a Col2Cre;Gpr126fl/fl mouse model, mice develop scoliosis and 
pectus excavatum. Neither scoliosis nor pectus excavatum were present in the DhhCre;Gpr126fl/fl 
(Karner et al., 2015), which deletes Gpr126 in neuronal tissue. Therefore the AIS phenotype is not a 
cause of neuropathy of radicular nerves.  
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4.6.8 Gpr126 is crucial for radial sorting and myelination in zebrafish 
Pogoda et al. published in 2006 a genetic screen, focused on disruption of myelination in zebrafish 
(Danio rerio)(Pogoda et al., 2006). To induce mutations in pre-meiotic germ cells, male zebrafish have 
been exposed to the mutagen N-nitroso-N-ethylurea (ENU). After a standard (in)-breeding scheme, 
homozygous mutants have been obtained in the F3 generation. F3 embryos have been screened by 
whole-mount in situ hybridization for myelin basic protein MBP mRNA expression. 13 mutations in 
10 different genes have been identified to disrupt myelination in the posterior lateral line nerve PLLn, 
a big sensory and easily visible nerve in zebrafish. In the mutations st49 and st63, MBP mRNA 
expression was not observed in peripheral nerves but normal in the CNS. Genetic mapping assigned the 
mutations to Linkage group 20 (Kelly et al., 2000) containing Gpr126. Sequencing revealed a mutation 
in Gpr126 for both mutants st49 and st63 and a standard complementation experiment to prove a 
mutation in the very same gene was not necessary. The mutation in st49 is leading to a premature stop 
codon just in front of the GPS domain and the mutation in st63 changes a highly-conserved cysteine to 
a tyrosine in the 7TM domain of the receptor. To show that the phenotype was indeed caused by Gpr126, 
they used a morpholino blocking the splicing of Gpr126 pre-mRNA which indeed resulted in a similar 
phenotype (phenocopy) deficient in peripheral myelination. In situ hybridization with Gpr126 mRNA 
showed expression of the Gpr126 in the sensory PLLn. Quantitative PCR of PLLn could detect 
continuous Gpr126 expression form embryo throughout adulthood. To ask whether Gpr126 expression 
in neurons or Schwann cells is needed for proper myelination, they generated chimera by transplanting 
fluorescently labeled wildtype cells into st49 mutants. All myelinating Schwann cells had a wt genotype 
and some of them were ensheating Gpr126 deficient axons leading to the conclusion that Gpr126 is 
crucial for myelination autonomously in Schwann cells. 
4.6.9 Gpr126 is crucial for myelination in mammals 
To determine if Gpr126 is equally important for myelination in mammals, the Talbot lab analyzed 
Gpr126 deficient mice generated by Taconic (Monk et al., 2011). In those mice, a selection cassette 
replaced exons 3 and 4 of the wildtype allele. Heterozygous Gpr126+/- mice were intercrossed and only 
26 of 334 or 7.8% pups were homozygous Gpr126-/-, which was way below the mendelian 25%. 
Knocking out Gpr126 was leading to increased embryonal lethality. At birth, Gpr126-/- pups are same 
size as heterozygous and wildtype littermates, but they fail to thrive, become immotile by P12 and die 
before weaning. Phenotypically, Gpr126-/- showed contractures of the joints. Sciatic nerves of 
Gpr126-/- mice were thinner and more translucent than nerves of wt mice. Transcription factor Sox10, 
expressed during early development in Schwann cells was identified in sciatic nerves of Gpr126-/- mice 
but they failed to express later transcription factors such as Dhh, Oct6, Egr2 or myelin basic protein 
MBP. Interestingly, CNS myelination of optic nerves by oligodendrocytes was not affected in 
Gpr126-/- mice. Axonal sorting of Schwann cells with axons was happening in a normal 1:1 fashion, 
but was severely delayed. All Schwann cells were arrested at the promyelinating stage and never 
generated any myelin. Furthermore, Remak bundles, in which a non-myelinating Schwann cell 
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ensheathes multiple axons, were not observed in Gpr126-/- mice. At postnatal day 4, Gpr126-/- mice 
showed significantly less axons leading to the conclusion that Gpr126 signaling is crucial for axonal 
maintenance. 
4.7 Ligands for Gpr126 
4.7.1 Laminin-211 
Laminin-211 was the first reported ligand for Gpr126. The basal lamina is crucial for Schwann cell 
development, it mainly consists laminin, collagen IV and heparin sulfate proteoglycans HSPGs. Only 
laminin but not collagen IV or HSPGs is sufficient to promote myelination (Eldridge et al., 1989). The 
formation of the basal lamina is essential for radial sorting and myelination. Laminin-211 (formerly 
known as Laminin-2) is a heterotrimeric protein composed of an α-2, β-1 and γ-1 chain encoded by the 
genes Lama2, Lamb2 and Lamc1. The Laminin-isoform 211 binds to β1-integrins and α-dystroglycan 
(Feltri and Wrabetz, 2005). Mice deficient for Laminin and β1-integrin show abnormal or absent radial 
sorting. And resembled the phenotype of Gpr126-/- mice. Laminins were considered to be very probable 
candidates for a Gpr126-ligand since adhesion GPCRs are well known for their ability to bind 
extracellular matrix molecules. Luo et al. already reported Collagen III as a ligand for aGpr56 (Luo et 
al., 2011). Interaction of β1-integrin and laminin-211 phosphorylates and activates downstream effector 
focal adhesion kinase FAK. p-FAK levels were not altered in Gpr126st47 mutants, indicating that 
Gpr126-NTF-signaling is bypassing FAK. In co-immunoprecipitation assays, Petersen et al. could pull 
down laminin-211 together with a Gpr126-NTF-hFc fusion protein in primary mouse astrocyte cultures, 
meningeal fibroblast cultures and P4 sciatic nerve lysates. A laminin-binding domain in Gpr126-NTF 
between aa 446 and 807was identified. Dorsal root ganglia DRGs cultured on laminin coatings of 
different concentrations showed an increased myelin basic protein expression on higher concentrations 
of laminin-211. Lama2 knockdown in hypomorphic Gpr126st63 mutants resulted in reduced PLLn Mbp 
expression and Gpr126st63 mutants were rescued by injection of a lama2 overexpression construct. 
4.7.2 Stachel 
Gpr126 has been reported to signal via G protein coupling (Mogha et al., 2013). From other adhesion 
GPCRs it is known that deletion of amino-terminal ectodomains can lead to increased receptor activity 
(Okajima et al., 2010; Paavola et al., 2011). To elucidate aGPCR activation, Liebscher et al generated 
amino-terminally truncated variants of Gpr126. The receptor variants were constitutively active unless 
a domain between the GPS cleavage site and TM1 was deleted. The tethered agonist at the very 
carboxy-terminus of the ectodomain was called Stachel. The authors propose a model in which ligands 
bind to the ectodomain of Gpr126 leading to a conformational change or simply a mechanical 
dislocation. Both would expose the “Stachel” sequence and activate the receptor (Liebscher et al., 
2014). 
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4.7.3 Collagen IV 
Collagen IV is a main component of the basal lamina, which drives myelination (Bunge et al., 1986), 
therefore it was besides of laminin a probable interacting factor with Gpr126. Paavola et al. (Paavola et 
al., 2014) showed that collagen IV indeed binds to Gpr126, the Cub and PTX domains mediate the 
interaction with collagen IV and cAMP levels in Gpr126 overexpressing Hek cells increase after 
collagen IV treatment. Furthermore, amino-terminally truncated Gpr126 is constitutively activated. The 
authors propose a model in which the NTF of Gpr126 inhibits receptor activation and collagen IV 
dislocates the NTF leading to receptor activation with cAMP increase. 
4.8 NTF of GPR126 is sufficient for radial sorting 
Zebrafish mutants gpr126st49 have a point mutation resulting in a premature stop codon near the GPS 
site. Therefore, the amino-terminal fragment NTF is intact but the entire carboxy-terminal fragment 
CTF is absent. Radial sorting is normal in Gpr126st49 leading to the conclusion that NTF is sufficient 
for radial sorting. Petersen et al. used TALENs to create Gpr126st47 mutants which have an indel 
resulting in a frame shift and truncated Gpr126 in the CUB domain. The gpr126st47 mutants missed 
radial sorting (Petersen et al., 2015). Transheterozygotes, containing alleles of both Gpr126st49 and 
Gpr126st47 mutants were significantly rescued in radial sorting. 
4.9 CTF of Gpr126 activates cAMP dependent myelin gene expression 
Schwann cells in Gpr126st49 mutants are arrested in promyelinating state. By elevation of cAMP levels 
through administration of forskolin, Monk et al could drive expression of myelin genes in Gpr126st49 
mutants. Without radial sorting, there was no expression of myelin genes in Gpr126st47 mutants and 
forskolin could not promote radial sorting in gpr126st47 mutants. Petersen et al conclude that NTF is 
responsible for radial sorting and CTF raises cAMP levels resulting in expression of myelin genes Mbp 
and P0 in promyelinating Schwann cells. 
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5 Scientific Aims 
The cellular prion protein PrPC became ubiquitously known for its potential capability to undergo 
conformational change in the context of fatal neurodegenerative diseases. However, the physiological 
role of this highly conserved protein is still vague. Our lab previously reported a chronic peripheral 
neuropathy as a common trait in four independent Prnp-/- mouse lines and showed the involvement of 
a non-cell autonomous function where axonal PrPC is essential for maintenance of Schwann cells. In 
my thesis I studied the effect of the physiologically occurring amino-terminal flexible tail FT of PrPC 
as a signaling peptide for myelin maintenance in Schwann cells. I asked if FT can bind to Schwann 
cells, if the interaction is based on binding to a proteinacious receptor, what class of receptors is 
involved and  what major signaling pathways are activated by FT signaling.  Finally, I aimed to identify 
the responsible FT receptor on Schwann cells with the goal to understand the molecular mechanism 
leading to chronic demyelinating neuropathy in Prnp deficient mice. The novel insights into FT 
signaling in Schwann cells could offer innovative therapeutic strategies for the treatment of 
neuropathies, a highly prevalent disorder. 
  





Mice were bred in specified-pathogen free facilities at the University Hospital Zurich and Washington 
University, and housed in groups of 3-5, under a 12 h light/12 h dark cycle (from 7 am to 7 pm) at 
21±1°C, with sterilized chow (Kliba No. 3431, Provimi Kliba, Kaiseraugst, Switzerland) and water ad 
libitum. Animal care and experimental protocols were in accordance with the Swiss Animal Protection 
Law, and approved by the Veterinary office of the Canton of Zurich (permits 123, 130/2008, 41/2012 
and 90/2013). The following mice were used in the present study: C57BL/6J, PrnpZH1/ZH1 (Bueler et al., 
1992), co-isogenic C57BL/6J PrnpZH3/ZH3 and PrnpWT/WT control mice(Nuvolone et al., 2016) and 
Schwann cell-specifc DhhCre;Gpr126fl/fl mutants. Mice of both genders were used for experiments unless 
specified. Archival tissues from previous studies (Bremer et al., 2010b; Nuvolone et al., 2016) were also 
analyzed. 
6.2 Primary Schwann cell culture 
Sciatic nerves from postnatal day 2-5 were dissected using microsurgical techniques. Nerves were 
dissociated in serum-free DMEM supplemented with 0.05% collagenase IV (Worthington) for 1h in the 
incubator. Sciatic nerves were mechanically dissociated using fire-polished Pasteur pipettes. Cells were 
filtered in a 40 µM cell strainer and washed in Schwann cell culture medium (DMEM, Pen-Strep, 
Glutamax, FBS 10%) by centrifugation at 300g for 10 min. Resuspended cells were plated on 3.5 cm 
petri dishes previously coated with poly-L-lysine 0.01% (wt/vol) and laminin (1 mg/ml). Laminin (Cat. 
No: L2020; from Engelbreth-Holm-Swarm murine sarcoma basement membrane) and poly-L-lysine 
were obtained from Sigma-Aldrich. 
6.3 Purification of recombinant proteins 
Full-length recombinant PrP (recPrP, residues 23-231) and globular domain (GD, residues 121-231) 
were purified as previously described (Hornemann et al., 2009; Lysek and Wuthrich, 2004; Zahn et al., 
1997). The generation of the GST fusion FT-PrP expression vector (pGEX-KG FT-PrP) was described 
previously; a modified purification protocol was used (Guillot-Sestier et al., 2009). The FT-PrP 
expression vector was transformed into BL21 (DE3) strain of Escherichia coli (Invitrogen). Bacteria 
were grown in Luria-Bertani medium to an OD of 0.6, and the expression of the fusion protein was 
induced with 0,5mM isopropyl-1-thio-β-D-galactopyranoside (AppliChem). Cells were then grown for 
another 4h at 37 °C and 100 rpm shaking. Cells were pelleted at 5000g for 20 min at 4 °C (Sorvall 
centrifuge, DuPont). The pellet was resuspended on ice in lysis buffer (phosphate-buffered saline 
supplemented with complete protease inhibitors (EDTA-free, Roche), phenylmethyl sulfonyl fluoride 
(Sigma) and 150 µM lysozyme (Sigma) and incubated on ice for 30 min. Triton-X 100 (1%), MgCl2 
(10mM) and DNase I (5 µg/ml, Roche) were added, and the lysate was incubated on ice for 30 min. The 
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lysate was than centrifuged for 20 min at 10’000g at 4°C. Glutathione sepharose beads were washed 
with PBS and incubated with the cell lysate for 1h at 4°C on a rotating device. Beads were packed into 
a column and washed with PBS until a stable baseline was reached as monitored by absorbance at A280 
using an ÄKTAprime (GE healthcare). The fusion protein was cleaved on the beads with 5U/ml 
Thrombin (GE Healthcare) for 1h at room temperature under agitation. For thrombin removal, 
benzamidine sepharose beads were added and incubated for 1h at 4°C on a rotating wheel. Protein 
preparations were analyzed by 12% NuPAGE gels followed by Coomassie- or silver-staining. To 
achieve a higher purity of the protein, we next applied the protein to a sulphopropyl (SP) sepharose 
column equilibrated with 50mM Tris-HCl buffer, pH=8.5. Elution was performed with a linear NaCl 
gradient ranging from 0–1000 mM. Fractions containing the protein were collected and concentrated 
(AMICON; MWCO 3500). The protein was then injected in 500 µl portions into a size-exclusion 
chromatography system (TSK-GEL G2000SWXL column (Tosoh Bioscience)) and eluted with a linear 
gradient using PBS. Pure fractions were combined, concentrated and stored at -20°C. The purity of FT-
PrP was > 95-98 % as judged by a silver-stained 12% NuPAGE gel. 
6.4 Cell Culture 
SW10 cells and clones derived from it were all grown in DMEM medium supplemented with 10% fetal 
bovine serum (FBS), penicillin-streptomycin and Glutamax (all obtained from Invitrogen). HEK293T 
cells and clones derived therefrom were grown in DMEM-F12 medium supplemented with 10%FCS, 
penicillin-streptomycin and Glutamax (all obtained from Invitrogen). Human Gpr126 (NM_020455), 
Gpr124, Gpr64, Gpr56, Gpr133, Gpr56 and Gpr176 expression plasmids (pCGpr126-V5, pCGpr124-
V5, pCGpr65-V5, pCGpr56-V5, pCGpr133-V5, pCGpr56-V5 and pCGpr176-V5) were generated by 
PCR amplification of the respective cDNA followed by TOPO cloning into the pCDNA3.1/V5-His-
TOPO vector. The cDNA was in frame with the V5 tag (sequence: GKPIPNPLLGLDST) at the C 
terminus. HEKGPR126, HEKGPR176 cells were generated by transfecting 1µg of plasmid in one well of a 
subconfluent 6-well plate using 3µl Fugene (Roche) according to the manufacturer’s protocol. 24h after 
transfection, cells were transferred to a 10cm dish and grown in selective medium containing 0.4 mg/ml 
G418 (Invitrogen) until emergence of resistant colonies. A limiting dilution was carried out to obtain 
clonal lines. Membrane expression of the transgene was assessed in the selected clones by confocal 
microscopy using 1:100 diluted anti-V5 antibody (Invitrogen) and the Cytofix/Cytoperm kit 
(Pharmingen Cat. Nr. 554714), according to manufacturer’s protocol. 
6.5 Cerebellar granule neuronal culture 
Cerebellar granule neurons were generated from 7-8 day old PrnpZH1/ZH1 mice with methods described 
previously (Schulz et al., 1996). Cultures were plated at 350,000 cells/cm2 in Basal Medium Eagle 
(BME) (Invitrogen) with 10% (v/v) FCS and maintained at 37°C in 5% CO2. 
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6.6 Plasmids and Transfections 
pCDNA-PrPC was generated by cloning murine PrPC into pCDNA3.1 vector as described previously 
(Dametto et al., 2015). Site-specific mutagenesis kit (Stratagene) was used to induce alanine 
substitutions of QPSPG and KKRPK domains in PrPC. Primers used for generating Ala-QPSPG plasmid 
are: forward- GTG GAA GCC GGT ATC CCG GGG CGG CAG CCG CTG CAG GCA ACC GTT 
ACC C reverse:  GGG TAA CGG TTG CCT GCA GCG GCT GCC GCC CCG GGA TAC CGG CTT 
CCA C. Primers for Ala-KKRPK are: forward- CTA TGT GGA CTG ATG TCG GCC TCT GCG CAG 
CGG CGC CAG CGC CTG GAG GGT GGA ACA CCG, reverse: CGG TGT TCC ACC CTC CAG 
GCG CTG GCG CCG CTG CGC AGA GGC CGA CAT CAG TCC ACA TAG. Transfections were 
performed with Lipofectamine 2000 (Invitrogen) according to manufacturer’s protocol. 3µg of DNA 
was used per well of a 6-well plate. 24h post transfections, cells were washed using PBS, and fresh 
medium was added to the cells.  
6.7 Immunoprecipitation 
HEK293T and HEKGPR126 cells growing in T75 flasks at 50% density were treated with recombinant FT 
or GD (2µM, 20 min). Cells were washed twice in PBS and lysed in IP buffer: 1% Triton X-100 in PBS, 
1x protease inhibitors (Roche) and Phospho stop (Roche) for 20 min on ice followed by centrifugation 
at 5000 rpm for 5 min at 4°C. BCA assays were performed to quantify the amount of protein, and 500 
µg of protein was used for Immunoprecipitations. 2 µg of anti-V5 antibody were added to the cell lysate 
and incubated on a wheel rotator overnight at 4°C. On the following day, Protein G dynabeads 
(Invitrogen) were added to the samples and incubated for further 3h on the wheel at 4°C. Beads were 
washed three times, 5 min each using the IP buffer followed by addition of 2x sample buffer containing 
DTT (1mM final). Samples were heated at 95°C for 5 min, loaded on 4-12% Novex Bis-tris gels 
(Invitrogen), and migrated for 1.5h at 150V followed by western blotting. Immunoprecipitations were 
performed by adding 2 µg of POM2 antibody to 500µl of cell medium and incubating overnight on a 
wheel rotator at 4°C. Protein G beads were then added, and incubation on a wheel rotator at 4°C was 
performed again. 
6.8 RNA Isolation and quantitative PCR 
RNA extraction and quantitative PCR was performed as described previously (Bremer et al., 2010b). 
The following primers were used: EGR2 fw: 5’-AATGGCTTGGGACTGACTTG-3’; EGR2 rev: 5’-
GCCAGAGAAACCTCCATT-3’ CA; GAPDH fw: 5’-CCACCCCAGCAAGGAGAC-3’; GAPDH 
rev: 5’-GAAATTGTGAGGGAGATGCT-3’. 
6.9 Zebrafish mutant strains and analysis  
Adult zebrafish were maintained in the Washington University Zebrafish Consortium facility 
(http://zebrafishfacility.wustl.edu/) and all experiments were performed in compliance with institutional 
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protocols. Embryos were collected from harem matings or in vitro fertilization, raised at 28.5°C, and 
staged according to standard protocols (Kimmel et al., 1995). The gpr126st49 and gpr126st63 mutants 
were described previously (Monk et al., 2009; Pogoda et al., 2006). 
6.10 Zebrafish peptide treatment, immunostaining, and quantification 
gpr126st63 or gpr126st49 mutants were collected from homozygous mutant crosses and WT larvae were 
collected from AB* strain crosses and raised to 50 hours post fertilization (hpf). FT23-50 treatment of 
gpr126 mutants was performed as previously described (Liebscher et al., 2014). Briefly, egg water was 
then replaced with either 20 µM FT23-50 in egg water or egg water containing an equivalent volume of 
DMSO. At 55 hpf, larvae were washed twice and raised in egg water to 5 days post fertilization (dpf). 
WT and gpr126 larvae were fixed in 2% paraformaldehyde + 1% tricholoroacetic acid in phosphate 
buffered saline, and Mbp and acetylated tubulin immunostaining was performed as described previously 
(Lyons et al., 2005; Monk et al., 2009). Expression scoring was performed with observer blind to 
treatment according to the following rubric: “strong” = strong and consistent expression throughout 
PLLn, “some” = weak but consistent expression in PLLn, “weak” = weak and patchy expression in 
PLLn, “none” = no expression in PLLn. N = three independent replicate gpr126st63 assays and one 
gpr126st49 assay. n = 87 DMSO-treated gpr126st63 larvae, 81 Prp-FT-treated gpr126st63 larvae, n = 27 
DMSO-treated gpr126st49 larvae, n = 25 Prp-FT-treated gpr126st49 larvae. Fluorescent nerve images were 
analyzed using the Fiji software (Schindelin et al., 2012). A rectangle region-of-interest (ROI) was 
drawn longitudinally over the fluorescent nerve. The longitudinal grey-scale histogram of the myelin 
basic protein (MBP) was normalized pixel-by-pixel to the corresponding intensity of the acetylated 
tubulin (AcTub). The size of the measured ROIs was kept constant across different treatment 
modalities.  
6.11 Flow cytometry 
SW10 cells were grown in P75 flasks at 50% density, rinsed with PBS, and detached from culture flasks 
with dissociation buffer containing EDTA (GIBCO). After detaching, cells were washed to remove 
residual EDTA and counted using a Neubauer chamber. Batches of 105 SW10 cells were transferred to 
FACS tubes, treated with HA-tagged recombinant peptides for 20 minutes, washed, and incubated with 
Alexa-488 conjugated anti-HA antibody for 30 minutes. After further washes and centrifugations, cells 
were resuspended in 200µl of FACS buffer (PBS +10% FBS) and analyzed with a FACS Canto II 
cytofluorimeter (BD Biosciences). Data were analyzed using FloJo software. 
6.12 Western blot analysis 
Schwann cells were lysed in cell-lysis buffer (Tris-HCl 20mM, NaCl 137mM, Triton-X-100 1%) 
supplemented with protease inhibitor cocktail (Roche complete mini). The lysate was homogenized by 
passing several times through a 26G syringe, and cleared by centrifugation at 8000g, 4°C for 2 min. in 
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a tabletop centrifuge (Eppendorf 5415R). Protein concentration was measured with the BCA assay 
(Thermo Scientific). 10 µg total protein was boiled in 4 x LDS (Invitrogen) at 95°C for 5 min. After a 
short centrifugation, samples were loaded on a gradient 4-12% Novex Bis-Tris Gel (Invitrogen) for 
electrophoresis at constant voltage of 200V. Gels were transferred to PVDF membranes with the iBlot 
system (Life technologies). Membranes were blocked with 5% Top-Block (Sigma) in PBS-T for 1h at 
room temperature. Primary antibody was incubated overnight in PBS-T with 5% Top-Block. 
Membranes were washed three times with PBS-T for 10 min. and incubated for 1 hour with secondary 
antibodies coupled to horseradish peroxidase at room temperature. After three washes with PBS-T, the 
membranes were developed with Crescendo chemiluminescence substrate system (Millipore). Signals 
were detected using a Stella 3200 imaging system (Raytest, Straubenhardt, Germany). 
6.13 Antibodies 
Monoclonal antibodies against PrPC were obtained and used as described previously (Polymenidou et 
al., 2008).  Fab3 and Fab71 antibodies were generated using the phage display technology and their 
epitopes were mapped with overlapping peptides. Anti AKT, p-AKT were obtained from Cell signaling 
and used at 1:2000 dilutions for western blotting. Anti-p75NGF receptor antibody was obtained from 
Abcam and used at 1:200 dilutions for immunofluorescence. Anti V5 antibody was from Invitrogen and 
used at a dilution of 1:500 for western blot and 2µg of the antibody was used for immunoprecipitation 
on 500µg of cell lysate. 
6.14 Cyclic AMP measurements 
In the Direct cAMP ELISA assay, cAMP levels were assessed with a colorimetric competitive 
immunoassay (Enzo Life Sciences). Quantitative determination of intracellular cAMP was performed 
in cells or tissues lysed in 0.1 M HCl to stop endogenous phosphodiesterase activity and to stabilize the 
released cAMP. SW10 or HEK293T cells (100’000 cells /well) were plated in 6-well plates to a ca. 50% 
density. Cells were treated with conditioned media or recombinant peptides (2µM, unless specified) for 
20 minutes unless otherwise mentioned. Cells were lysed with 0.1M HCl lysis buffer (Direct cAMP 
ELISA kit, Enzo). To ensure complete detachment of cells cell scrapers were used. Lysates were 
homogenized with 26G needle and syringe before clearing by centrifugation at 600g for 10 min. The 
subsequent steps were performed according to the manufacturer’s protocol based on competition of 
sample cAMP with a cAMP-alkaline phosphatase conjugate. Cyclic AMP levels were calculated using 
a cAMP standard curve in the case of ELISA based assay. Finally, cAMP concentrations were 
normalized to total protein content in each sample. cAMP changes are represented as fold changes to 
the respective controls. For each experiment, at least three independent biological replicates were used. 
For normalization purposes, the median value of the respective control sample was defined as “1”. All 
measurements within each panel were normalized to this control value.  
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6.15 Generation of Schwann cell lines devoid of Gpr126  
We designed two CRISPR short-guide RNA (sgRNAs) against exon 2 of Gpr126 (upper Guide 
CCTGTGTTCCTCTCTCAGGT and lower Guide AACAGGAACAGCAGGGCGCT). The DNA 
sequences corresponding to the sgRNAs were cloned into expression plasmids and transfected with 
EGFP-expressing Cas9-nickase plasmids. Single EGFP-expressing Schwann cells were isolated with a 
FACS sorter (Aria III). To determine the exact sequence of indels induced by genome editing we 
amplified the sgRNA-targeted locus by PCR and subcloned the fragments into blunt-TOPO vectors. 
Ten colonies per cell line were sequenced and showed distinct indels on each allele. A clonal subline 
devoid of Gpr126 was used for further studies. This cell line possessed insertions on both the alleles; a 
49bp insertion at position 118 and a 5bp insertion at position 84 on each allele. Both insertions led to a 
frameshift and to the generation of premature stop codons leading to early translation termination. 
6.16 Promoter luciferase assay 
Luciferase reporter constructs were generated containing a 1.3kB sequence upstream of the 
transcription-starting site of Egr2. SW10 Schwann cells were transfected with Egr2 reporter construct 
and a renilla plasmid using lipofectamine 2000. After one day in vitro, Schwann cells were treated with 
recombinant full-length PrP (23-231), the globular domain of PrP (121-231) or PBS control. Luciferase 
activity was measured 24 hours after stimulation with Dual-Luciferase Reporter Assay System 
(Promega) according to the manufacturer’s recommendations. Results were normalized to renilla 
transfection controls. 
6.17 Immunocytochemistry 
Glass coverslips were placed in 12-well plates (Thermo scientific) and coated with 0.01% wt/vol Poly-
l-lysine solution (Sigma) overnight at room temperature. Coverslips were washed three times with 
ddH2O and dried for 2h in a laminar-flow hood. Schwann cells were seeded and cultured at 50% density. 
Cells were treated with recombinant FT-PrP, full length recPrP or C1-PrP for 20 min., and washed with 
serum-free DMEM. Cells were further washed with PBS followed by fixation with 4% 
paraformaldehyde. Fixed cells were incubated in blocking buffer (PBS+10%FBS) for 1h. Cells were 
treated with various primary antibodies followed by washes and incubation with Alexa 488 and Alexa 
647 tagged rabbit or mouse secondary antibodies (Life technologies). Imaging was performed by Leica 
SP2 confocal microscope using a 20x objective; images were processed by Image J software. 
6.18 Transmission electron microscopy 
Transmission electron microscopy was performed as previously described (Nuvolone et al., 2016). 
Briefly, mice under deep anesthesia were subjected to transcardial perfusion with PBS heparin and 
sciatic nerves were fixed in situ with 2.5% glutaraldehyde + 2% paraformaldehyde in 0.1 M phosphate 
buffer, pH 7.4 and embedded in Epon. Ultrathin sections were mounted on copper grids coated with 
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Formvar membrane and contrasted with uranyl acetate/lead citrate. Micrographs were acquired using a 
Hitachi H-7650 electron microscope (Hitachi High-Tech, Japan) operating at 80 kV. Brightness and 
contrast were adjusted using Photoshop. For quantification of Remak bundles and onion bulb like 
structures, images were captured at 1500X magnification and axon numbers and abnormal onion bulb 
like structures were counted manually. Quantification was performed in a blinded fashion by assigning 
numbers to the images and upon completion of quantification genotypes were revealed. 
6.19 Recombinant peptides 
HA-tagged and untagged synthetic peptides were produced by EZ Biosciences. A stock solution of 2mM 
was prepared by dissolving the peptides in PBS and they were used at a final concentration of 2µM 
unless specified. The sequences all the peptides used in this study can be found in Table 1. 
 




7.1 Starting a binding assay 
From previous work of Juliane Bremer we learned that axonal PrPC is essential for Schwann cell 
maintenance in a non-cell autonomous fashion. At the very beginning of my studies, the most obvious 
question was if PrPC would directly interact with Schwann cells in a simple binding assay. A direct 
interaction clearly represented the easiest mechanistic explanation. Alternatively, PrPC could have been 
one of many components in a multiprotein complex or the executive function could have been even more 
indirect through modulation of ion channels or structural alterations of the nerve-Schwann cell junction. 
To begin a binding assay, I had to express and purify the prion protein and some larger oligopeptides 
representing shorter parts of the prion protein. 
7.2 Expression of recombinant N-terminal Prion potein 
Full length PrPC and the globular domain (GD, residues 121-231) were already available in our repository. 
The aminoterminal flexible tail of PrPC (FT, residues 23-110) had to be expressed and purified at first. The 
flexible tail FT presented some specific difficulties for expression and purification. FT is a completely 
unstructured polypeptide containing the charge cluster 1 of charged amino acids at its N-terminus. Short 
unstructured peptides are known to be quickly degraded by proteases. Charged peptides can show 
unwanted interactions with other peptides sticking to them or they will stick to every surface and can only 
be eluted under harsh conditions. Our FT expression vector was generated by Guillot-Sestier (Guillot-
Sestier et al., 2009) by cloning residues (23-110) of PrP into the pGEX-KG vector, which conveniently 
allows to express constructs with a GST-tag attached for purification. I transformed the N1-pGEX vector 
to BL21 E.coli cells (Invitrogen) by heat shock and cultered E. coli in buffered flasks containing Luria-
Bertani medium. Once an optical density of 0.6 was reached, I induced the cells with 0,5mM isopropyl 1-
thio-β-D-galactopyranoside (AppliChem).  
7.3 Protein purification with GST-affinity chromatography 
Then, I resuspended the pellet in lysis buffer on ice (see mateials and methods for detailed protocol).The 
supernatant containing the FT was then incubated with Glutathione sepharose beads. Beads were packed 
into a column and washed under control of A280 absorption using an Äkta prime purifier. The pGEX-KG 
vector provided a Thrombin recognition site in between the GST and the FT-sequence. Hence, the FT 
could be cleaved on column using 5U/ml Thrombin (GE Healthcare). I removed Thrombin with 
benzamidine sepharose. Finally, I could analyze the prurified protein by gel-electrophoresis and Coomassie 
staining wich resulted in a clearly visible band at 9kD (Fig. 7.1 A). Coomassie blue can stain peptides in 
the µg range and I next performed a silver staining, which could show impurities in the nanogram range 
(Fig. 7.1 B). I found some higher running bands, which could be di-, tri- or polymers of FT or represent 
different E. coli derived peptides. Smaller bands were most probably degraded parts of FT. 
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                A  
Figure 7.1 çImpurities obvious in silver gel. A Coomassie gel showing a purified 9kd protein in increasing amounts. B Silver 
staining of the very same gel depicts impurities in the ng range.  
7.4 Cation exchange chromatography 
For my binding assay and even more for the later signaling assays such as the cAMP assay I needed highly 
pure protein preparations. Especially heat shock proteins are abundant in E. coli and can interact in many 
downstream assays and applications. Therefore, I intensified my purification process by adding a cation 
exchange chromatography step. I hypothesized that main impurity could come from residual GST. The 
isoelectric point (pI) of FT can be calculated and equals 9.5, whereas the pI of GST is 6. To get rid of GST, 
I had to choose a pH in between 6 and 9.5, when FT was positively and GST negatively charged. The 
fractions were adsorbed to sulphopropyl sepharose in Tris-HCl buffer at a pH of 8.5. Elution was performed 
with a linear NaCl gradient and resulted in a major peak at 200mM NaCl (Fig. 7.2). 
 
Figure 7.2 | Cation exchange chromatography. CEC using sulphopropyl sepharose in Tris-HCl buffer at a pH of 8.5. Elution 
with a linear 0-500mM NaCl gradient. A clear UV-peak is visible shortly after 200mM NaCl (Äkta prime). 
7.5 Size exclusion chromatography 
To further enhance the purity of our protein preparations, I performed size-exclusion chromatography on 
a high performance liquid chromatography (HPLC) TSK-GEL G2000SWXL column (Tosoh Bioscience). 
Size exclusion chromatography separates peptides by size and shape. The polymer beads packed in the 
column offer many pores where smaller peptides can hide during elution. In contrast, large peptides cannot 
10kD - 
B 
THE ROLE OF AXONAL PRION PROTEIN IN MYELIN MAINTENANCE 
36 
 
enter the small pores and are eluted instantaneously. By help of size exclusion chromatography I was able 
to get rid of a larger contaminant and still collected a nice protein peak in the fractions D9-D5 (Fig. 7.3). 
 
Figure 7.3 | Size exclusion chromatography. Protein absorption at 280nm showing a larger contaminant in fraction B1 and the 
FT-peak in fractions D9-D5. 
Enhanced purification with serial ion exchange chromatography and size exclusion chromatography 
resulted in higher purity as seen in (Fig. 7.4) on a silver gel. 
                        
 
Figure 7.4 | Compraison of pre- and postpurified peptide preparation. Silver gel of FT preparation after affinity 
chromatography only (lane 1) and after additional ion exchange and size exclusion chromatography (lane 2). M = marker. Lane 2 
shows a single band at 9kD. No other peptides appear in the ng range. 
7.6 Western Blotting 
I then performed a Western Blot using a POM 11 antibody recognizing the FT fragment in order to ensure 
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Figure 7.5 | Immunodetection of recombinant FT. Western Blot using POM 11 antibody recognizing the FT. The band at 9kD 
was clearly detected. 
7.7 PrPC binds to Schwann cells 
At the very beginning of my thesis I started with a simple binding experiment and assessed if full-length 
PrPC or fragments thereof would stick to primary Schwann cell cultures (PSC) prepared from sciatic nerves 
of PrnpZH1/ZH1 mice (Bueler et al., 1992). In order to avoid confounding homotypic interactions between 
resident and incoming PrPC (Santuccione et al., 2005), I decided to use PSC from Prnp deficient mice. I 
exposed PSCs to bacterially expressed proteins corresponding to murine full-length PrPC lacking its N-
terminal secretory signal peptide (recPrP, residues 23-231), isolated flexible tail of PrPC (FT, residues 23-
110), or its refolded globular domain (GD, residues 121-231). Then, I treated the PSCs with POM1 and 
POM2 antibodies (Polymenidou et al., 2008) recognizing the GD and the FT, respectively and assessed 
binding by immunocytochemistry. To my surprise, both recPrP and the FT, but not the GD, were found to 
stain PSC, indicating an interaction of amino-terminal PrP and the Schwann cell surface (Fig. 7.6). 
 
Figure 7.6 | The prion protein binds to Schwann cells. Primary Schwann cells were isolated from the sciatic nerves of 
PrnpZH1/ZH1 mice and grown on coverslips. Cells were exposed for 20 min to recombinant PrPC, FT, or GD (2µM), fixed, and 
stained with POM2 (FT, PrPC) or POM1 (GD). Antibodies were visualized in the green channel and nuclei were stained with 
DAPI (blue). PrPC and FT, but not GD, adhered to the cells. Scale bars: 25µm 
7.8 SW10 Schwann cell line 
The generation of PSC is laborious and my promising first results suddenly created a need for robust and 
quickly growing Schwann cells. At ATCC I purchased the Schwann cell line SW10 and analyzed them for 
PrP expression which I could confirm to be present by Western blot (Fig. 7.9 B).  
10kD - 




Again to avoid confounding interactions between resident and incoming PrPC, I decided to ablate Prnp in 
SW10 cells using transcription activator-like effector nucleases (TALEN). Therefore, I transfected SW10 
cells (Lipofectamine, Invitrogen) with the TALEN Upper Guide, the TALEN lower guide and an EGFP 
transfection control. The first day after transfection, I checked the efficacy by fluorescence microscopy 
and around 30% of cells could be transfected (Fig. 7.7).  
A  B  
C  D  
Figure 7.7 | Transfection of SW10 cells. A: Transfection with TALEN upper guide, TALEN lower guide and EGFP transfection 
control. B. Fluorescence microscopy with positively transfected cells visible (around 30%). C: Control SW10 treated with empty 
vector and Lipofectamine. D: Fluorescence microscopy of control without any positive cells. 
In order to get clonal cell lines, I FACS-sorted positively transfected cells in 96-well plates. After 4 weeks 
of cell culture, I could detect cell medium discoloration in 7 wells and growth of 7 different clones was 
realized (Fig. 7.8). 
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A  B  
Figure 7.8 | Single cell FACS sorting. A: EGFP positive single cells were FACS-sorted in 96-well plates. Growth was detected 
after 4 weeks by yellow discoloration of the cell medium as seen in well 4G. B: Clonal cell bulk in well 4G from A.  
One cell clone called SW10∆PrP contained a point mutation in the coding region of Prnp leading to a 
frameshift and a premature stop codon (Fig. 7.9 A) that abolishes PrPC expression. I could prove complete 
ablation of PrPC by Western Blot with POM1 antibody (Fig. 7.9 B). 
A  B  
Figure 7.9. Sequencing of cell clone. A: Schematic representation of the target region for transcription activator-like 
endonucleases (TALEN) in the Prnp gene. Target guides are indicated by arrows. Gene editing resulted in a deletion leading to a 
frame shift in the PrPC coding sequence (designated as conflict in the figure) and a premature stop codon identified by sequencing. 
B: Wild-type SW10 cells and a subclone isolated after treatment with TALEN (termed SW10∆PrP) were probed by Western blotting 
using anti-PrP antibody (POM1). SW10∆PrP showed complete abrogation of PrPC expression and was used for further experiments. 
Levels of actin on the same membrane were monitored to confirm equal loading of cell lysates onto the gel. 
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7.10 Confirmation of FT binding in SW10∆PrP 
To make sure that SW10∆PrP are comparable to PSC, I treated SW10∆PrP cells with recPrP, FT, or GD for 
20 min, and assessed binding by immunofluorescence with POM1 and POM2 antibodies (Fig. 7.10 + 7.11 
A+B). Confirming my previous results with PSC, recPrP and FT, but not GD, adhered to SW10∆PrP cells. 
Moreover, neither recPrP nor FT adhered to the PrPC-ablated hippocampal cell line HpL (Kuwahara et al., 






Figure 7.10 | Schwann cells selectively bind the Flexible Tail (FT) 
domain of PrPC. Prnp-ablated SW10 cells (SW10∆PrP) were exposed to 
recombinant PrPC, FT, or GD (“ligand”). Binding was assessed with 
antibodies POM1 or POM2 (red). Grey: nuclei (DAPI). Antibodies to 
p75NGFR were used to identify Schwann cells. PrPC and FT, but not GD, 
adhered to Schwann cells. Scale bar: 26 µM.  
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A   B      C  
Figure 7.11 | A-C: SW10∆PrP cells were treated with full-length recombinant (PrPC, residues 23-231), flexible tail (FT, 23-110), 
or globular domain (GD, 121-231). PrP epitopes were detected with POM2 (A) or POM1 (B) (red). Grey: DAPI. As expected, FT 
was detected only by POM2. Cells were also labeled with antibodies to the p75 nerve-growth factor receptor (yellow), a Schwann 
cell marker. PrPC and FT, but not GD, adhered to Schwann cells. Scale bar: 26 µm. C: As a control, the PrPC-deficient cell line 
HpL (Kuwahara et al., 1999) was treated with recombinant PrPC, FT, and GD as in panel A. None of the recombinant proteins 
adhered to HpL cells. Scale bars: 20 µm. 
7.11 What domain of FT is responsible for binding to Schwann cells? 
I next sought to identify the minimal region within the FT responsible for binding. In this experiment I 
used synthetical peptides (EZ Biosciences) to make sure that no bacterial contaminants were present. I 
exposed SW10∆PrP cells to a series of partially overlapping hemagglutinin (HA)-tagged synthetic peptides 
(2 µM, 20 min) and stained them with FITC-labeled anti-HA antibody (Fig. 7.12 A). Then, I measured 
binding with fluorescence flow cytometry. FT23-50, but neither FT39-66 nor any of the carboxy-proximal 
peptides (Table 1), showed binding (Fig. 7.12 B) suggesting that residues 23-33 are essential for the 
interaction.   
A               B  
Figure 7.12 | A: Localization of FT-derived peptides relative to PrPC domains. CC1 and CC2: charge clusters 1 and 2. OR: 
octapeptide repeats. Peptides are color-coded as in panel C. B: SW10∆PrP cells were exposed to FT-derived peptides (2 µM; 20 
min) carrying a carboxy-terminal hemagglutinin tag (HA). Binding was monitored by flow cytometry. Only peptide FT23-50 
showed strong binding. 
 












AlaKKRPK AAAPAPGGWNTGGSRYPGQGSPGGNRYP  
ColIV GPRGKPGVDGYNGSRGDPGYP 
ColIV-Mut AAAGAAGVDGYNGSRGDPGYP 
Table 1 | Sequence of synthetic peptides used in my study. The collagen-4 homology domain necessary for cAMP induction is 
highlighted in yellow. 
7.12 The FT receptor is a protein 
To elucidate whether the interaction partner of FT is a protein I treated SW10 cells with trypsin (2.5% w/v, 
10 min) in order to degrade the extracellular domains of membrane-resident proteins. Following trypsin 
inactivation, I added non-trypsinized SW10 cells labeled with the cell-tracking dye Deep Red. After the 
addition of HA-tagged FT23-50 (2µM), I monitored binding by cytofluorimetry with FITC-conjugated anti-
HA antibodies. 51% of non-trypsinized cells showed FT23-50 binding while only 5% of trypsinized cells did 
(Fig. 7.13).  These results suggest the involvement of a surface protein in the interaction of the FT with 
Schwann cells. 
 
Figure 7.13 | The FT recepotor is a protein. SW10 cells trypsinized, washed, 
and mixed with non-trypsinized SW10 cells labeled with Deep Red cell tracker. 
Cells were incubated with HA-tagged peptide FT23-50, and binding was visualized 
by flow cytometry. The Deep red signal (abscissa) was used to differentiate 
trypsinized from non-trypsinized cells. 51% of untreated cells, but only 5% of 
trypsinized cells, became decorated by FT23-50-HA, indicating that FT23-50 reacted 
with trypsin-sensitive surface molecules. 
 
 
7.13 The FT receptor is a non GPI-anchored protein 
Because PrPC is GPI-anchored and can undergo homotypic interactions, I wondered if the receptor might 
be a GPI-anchored protein. I therefore tested the binding of HA-tagged FT23-50 to SW10 cells treated with 
phosphoinositol phospholipase C (PI-PLC, 30' at 37°C), which cleaves GPI anchors. Cytofluorimetry 
revealed no altered binding after PI-PLC treatment, indicating that FT binding did not require GPI-
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anchored surface proteins. To monitor PI-PLC effectiveness, I monitored binding of POM2 to PrPC and 
found it to be greatly reduced indicating that PrPC had been stripped from cell surfaces (Fig. 7.14). 
                                 
Figure 7.14. | FT is not GPI-anchored. SW10 cells were digested (30 min) with phosphatidylinositol phospholipase C (PI-PLC, 
0.5 units), washed, and incubated with FT23-50-HA along with undigested Deep-Red labeled cells (left panel). The proportion of 
binders in the digested (34%) and the undigested samples (30%) was similar, indicating that the FT23-50 receptor was neither PrPC 
itself nor any other GPI-linked protein. To monitor the efficiency of PI-PLC treatment, we assessed POM2 binding to PrPC on 
both treated and untreated cells (right panel). POM2 binding was significantly decreased in PI-PLC treated cells (23%) compared 
to untreated cells (90%). 
7.14 37-kDa/67-kDa laminin receptor (LRP/LR) is not the major receptor for FT binding 
The 37-kDa/67-kDa laminin receptor (LRP/LR) has been reported to interact with the cellular prion protein 
PrPC (Hundt et al., 2001; Rieger et al., 1997). PrPC can bind directly to LRP/LR with a domain including 
aa 144-179. Since this domain is not part of FT, it cannot be responsible for FT binding to the receptor on 
Schwann cells. A second binding domain including aa 53-93 was reported to be heparin sulfate dependent. 
First I checked if laminin treatment blocking the LRP/LR is able to abolish FT binding to the FT receptor 
on Schwann cells and if steric hindrance induced by binding of an anti-LRP antibody can block FT binding. 
Therefore, I pretreated SW10 cells with laminin or α-LRP antibody followed by FT-GST incubation. I then 
could detect a surface binding signal by flow cytometry using an anti-GST antibody conjugated to Alexa 
488. Both laminin and α-LRP antibody were not sufficient to block binding of FT-GST to SW10 cells 
completely. Minor reduction in FT-GST binding was detected after LRP/LR blocking and therefore some 
minor binding of FT-GST to LRP/LR is possible but does not account for the entire binding of FT to 
Schwann cells.  
7.15 Sciatic nerves from Prnp-/- mice have less cAMP 
Next, I measured cAMP concentrations in sciatic nerve lysates mice of various ages (Bueler et al., 1992). 
At 4 days of age, Prnp ablated mice (PrnpZH1/ZH1) and WT sciatic nerves showed similar cAMP levels (Fig. 
7.15 A). At 4 weeks of age, I detected a trend towards decreased cAMP levels in PrnpZH1/ZH1sciatic nerves 
(Fig. 7.15 B). 
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A                   B     
Figure 7.15 | cAMP content of Sciatic nerves from Prnp-/- mice compared to BL6. cAMP was measured in sciatic nerves 
isolated from 4-day old (A) or 4-week old (B) BL6 and PrnpZH1/ZH1 mice. No difference was observed in cAMP levels in 4-day 
old mice, whereas 4-week old PrnpZH1/ZH1 mice displayed a trend towards decreased cAMP levels. N.S.: non-significant. Error 
bars represent SEM. Unpaired Student’s t-test. 
At 12-16 weeks, when CDP is incipient in PrnpZH1/ZH1mice, myelin damage is morphologically minimal 
and clinically silent (Bremer et al., 2010b), PrnpZH1/ZH1nerves exhibited significantly lower levels of cAMP 
than those of wild-type BL6 mice (Fig. 7.16 A, p=0.0115). Strictly isogenic C57BL/6J Prnp-/- mice 
(PrnpZH3/ZH3) reproduced the CDP phenotype (Nuvolone et al., 2016), sciatic nerve lysates from these mice 
(10-16 week old) also displayed significantly lower levels of cAMP than wild-type mice (Fig. 7.16 B).  
A                      B  
Figure 7.16 | Sciatic nerves from Prnp-/- mice have less cAMP compared to BL6 at 12-16 weeks. A: PrnpZH1/ZH1 sciatic nerves 
displayed significantly lower cAMP than wild-type BL6 nerves. B: Sciatic nerve from 10-week old PrnpZH3/ZH3 mice showed a 
significant decrease in cAMP (p= 0.0151). N.S.: non-significant. Error bars represent SEM. Unpaired Student’s t-test. 
7.16 Cell type specific PrPC expression dictates cAMP content in sciatic nerves 
Expression of PrPC in neurons, but not in Schwann cells, suffices to prevent demyelination in PrnpZH1/ZH1 
mice (Bremer et al., 2010b). Sciatic nerves from 12-16 week old tgNSE-PrP mice, expressing PrPC in 
neurons, showed cAMP levels similar to wild-type mice, whereas tgMBP-PrP mice, which express PrPC 
in oligodendrocytes and Schwann cells, showed significantly diminished cAMP levels in sciatic nerves 
(Fig. 7.17).  
4-day old 4-week old 




Figure 7.17 | Cell type specific PrPC expression dictates 
cAMP content in sciatic nerves. Selective PrPC expression 
by neurons (tgNSE-PrP), but not by Schwann cells 
(tgMBP-PrP) restored cAMP levels in sciatic nerves of 10-
16 week-old mice. Each dot represents an individual mouse 
(11-15 mice/group). N.S.: non-significant. Error bars 
represent SEM. Unpaired Student’s t-test. 
7.17 Treatment of PSC and SW10 with FT induces cAMP response 
I  asked whether FT binding induces cAMP. PSC and SW10 cells were treated with FT (0.1-5 µM) for 20 
min, and cAMP levels in cell lysates were measured. PrnpZH1/ZH1 PSC (Fig. 7.18 A) and SW10 cells (Fig. 
7.18 B) reacted to FT, but not to GD, with a concentration-dependent cAMP increase. Dose-response 
analyses performed on PSC revealed an EC50 of 860 nM for FT (Fig. 7.18. C).  
A            B  
 
Figure 7.18 | FT induces cAMP. A: Primary PrnpZH1/ZH1 
Schwann cells were seeded in a 6-well plates and treated (20’) 
with increasing concentrations of recombinant FT or with 10 µM 
GD. Ø: untreated cells. cAMP levels were determined in cell 
lysates (5x105 cells/assay). Addition of FT, but not of GD, 
induced a concentration-dependent cAMP response in Schwann 
cells. Here and henceforth: *: p<0.05; **: p<0.01; ***: p<0.001.). 
B: SW10 cells were seeded in 6 well plates and treated (20’) with 
recombinant FT or GD (10 µM). Addition of FT, but not of GD, 
resulted in a concentration-dependent intracellular cAMP 
increase. C: Primary PrnpZH1/ZH1 Schwann cells (as described in 
A) were treated with FT (20’), and cAMP concentrations were 
determined by immunoassay, and a dose-response curve was 
interpolated. 
7.18 Transfected HEKPrP cells express a soluble FT 
Cytosolic cAMP spikes may result from spurious causes, including traces of bacterial contaminants, which 
may be difficult to identify. I transfected HEK293T cells, which express little endogenous PrPC, with a 
plasmid expressing murine PrPC or, for control, with an empty plasmid (henceforth called HEKPrP and 
C 
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HEKempty, respectively). Immunoprecipitation of spent medium with POM2 antibody showed that PrPC 
from HEKPrP cells underwent cleavage and release of soluble FT (Fig. 7.19 A). The spent medium from 
HEK 293T cells overexpressing PrPC contained ca. 37 ng FT/ml (Fig. 7.19 B).  
A      B  
Figure 7.19 | FT is cleaved and excreted by HEK cells transfected with murine PrPC.  A: HEK293T cells were transfected 
with an empty vector (HEKempty) or a plasmid expressing murine PrPC (HEKPrP). Cell medium was collected 48h after transfection 
and subjected to immunoprecipitation with monoclonal antibody POM2 (against PrPC), followed by western blotting using 
biotinylated POM2 and streptavidin-HRP. FT was observed only in the medium from HEKPrP cells. B: FT released into the 
conditioned medium of HEKPrP was immunoprecipitated using POM2 and visualized by Western blotting with biotinylated POM2. 
Dilutions of recombinant FT (3.125 - 100 ng) were used for calibration, and the concentration of FT released into the medium was 
estimated at 37 ng/ml. 
7.19 HEKPrP conditioned media raises cAMP in primary Schwann cells 
Exposure to conditioned medium from HEKPrP cells, but not from HEKempty cells, raised cAMP levels in 
PSC cultures generated from PrnpZH1/ZH1 mice (Fig. 7.20 A). These results confirm that eukaryotic PrPC 
can lead to the spontaneous formation of FT and, in turn, to paracrine cAMP induction. 
Immunoprecipitation of spent medium from PSC cultures and from sciatic nerves obtained from 10 week 
old C57BL/6 mice did not reveal any FT, indicating that little if any FT is cleaved from PrPC and released 
by Schwann cells (Fig. 7.20 B-C). 
A      B                   C  
Figure 7.20 | HEKPrP conditioned media raises cAMP in primary Schwann cells. A: cAMP concentrations in primary 
PrnpZH1/ZH1 Schwann cell cultures exposed to medium conditioned by HEK293T cells overexpressing wild-type murine PrPC 
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(HEKPrP, right). For control, HEK cells were transfected with a non-coding vector (HEKempty, left). FT-containing medium 
resulted in cAMP induction. B: Conditioned medium from primary BL6 Schwann cells cultures (PSCBL6) was subjected to 
immunoprecipitation with antibody POM2 (against PrPC) followed by Western blotting with POM2. For control, we used 
conditioned medium from HEK cells transfected with a non-coding plasmid (HEKempty) or a with a plasmid encoding murine 
PrPC (HEKPrP). FT was only detected in conditioned medium from HEKPrP cells (lane 2) but not in conditioned medium from 
two independent PSCBL6 cultures (lanes 3-4). Asterisks denote immunoglobulins detected by the secondary antibody. C: Sciatic 
nerves lysates obtained from 10 week old PrnpZH1/ZH1 and BL6 mice and subjected to immunoprecipitation with POM2 antibody 
followed by Western blotting with POM2. Full length PrPC, but no FT, was detectable in the immunoprecipitates from BL6 mice. 
7.20 Blocking of FT binding to Schwann cells with anti-PrP antibodies 
Blocking of FT binding to Schwann cells by use of anti-FT antibodies would allow me to determine the 
binding domain. Therefore, I first pre-incubated FT with POM2 recognizing an epitope in the octapeptide 
region and POM3 recognizing an epitope close to charge cluster 2. Both pre-treatments with POM2 and 
POM3 enhanced binding of FT to SW10 cells and we speculate that crosslinking of FT could be the reason 
for this observation. POM2 which recognizes several repetitive epitopes in the OR shows the most intense 










Figure 7.21 | Blocking of FT binding with anti-FT antibodies. A: Recombinant FT-GST was incubated with POM2 or POM3 
antibodies before treatment of SW10 Schwann cells. Binding was detected by flow cytometry using an anti-GST antibody 
conjugated to Alexa488. Both POM2 and POM3 pre-incubation resulted in increased FT binding. 
7.21 What part of FT induces the cAMP response? 
To assess, if the FT contains motifs responsible for inducing the cAMP response, I treated SW10∆PrP cells 
with the same synthetic peptides previously used to assess binding to Schwann cells. Peptide FT23-50 
induced cAMP, whereas FT34-69 and all carboxy proximal peptides were inactive (Fig. 7.22). These results 
suggest that residues 23-33, which contain the lysine-rich "charge cluster 1" (CC1), represent the 












































Figure 7.22 | FT23-50 induces a cAMP response. Synthetic peptides (27-44 residues) were added to SW10∆PrP cells (2 µM 
each, 20 min). Only FT23-50 induced cAMP. 
7.22 Selective blocking of FT23-50 with Fab fragments 
To test the latter prediction, I incubated FT23-50 with monovalent recombinant phage-derived 
miniantibodies recognizing the CC1 (Fab3) or the octapeptide repeats (Fab71) of PrPC. Preincubation with 
Fab3, but not with Fab71, significantly quenched the ability of FT23-50 to induce cAMP in SW10∆PrP cells 
(Fig. 7.23).  
 
Figure 7.23 | Fab3 recognizing the CC1 can significantly lower cAMP induction by FT. FT23-50 was preincubated with a 
two-fold molar excess of miniantibodies Fab3 or Fab71, and added to SW10∆PrP cells (20 min). Preincubation with Fab3, but not 
with Fab71, significantly quenched the FT-dependent cAMP spike. N.S.: not significant 
7.23 Is the PrPC receptor a GPCR? 
Because cAMP levels are often controlled by G-protein coupled receptors (GPCR)(Hanoune and Defer, 
2001), I reasoned that a GPCR may be involved in mediating the action of the FT, whose defective 
stimulation might trigger the CDP of PrPC-deficient mice. In the peripheral nervous system, myelination is 
controlled by Gpr126, a seven-membrane spanning adhesion GPCR expressed by Schwann cells (Monk et 
al., 2009; Pogoda et al., 2006). Gpr126-deficient mice die during embryogenesis (Waller-Evans et al., 
2010). Gpr126 undergoes constitutive cleavage resulting in the generation of N-terminal and C-terminal 
fragments (NTF and CTF) that remain non-covalently associated. NTF modulation of Gpr126 is thought 
to expose a tethered agonistic ligand (Liebscher et al., 2014). Because of these findings, Gpr126 seemed a 
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plausible candidate for mediating the effects of the FT. I therefore generated HEK293T cells stably 
overexpressing human Gpr126 or, for control, Gpr124 and Gpr176 (denoted HEKGpr126, HEKGpr124, and 
HEKGpr176 respectively). All transfected GPCRs contained a C-terminal 14-meric V5 epitope tag (Kasof 
and Gomes, 2001) and were found to be expressed at the cell surface (Fig. 7.24).  
 
Figure 7.24 | Panel of HEK cells expressing different GPCRs. Wild type HEK293T cells (HEKWT) or HEK293T cells 
overexpressing various GPCRs bearing V5 epitope tags (HEKGpr126, HEKGpr124, and HEKGpr176) were grown on coverslips and 
stained with anti V5 antibody (detecting tagged GPCRs; magenta). Nuclei were stained with DAPI (blue). Staining revealed cell 
surface expression of all transfected GPCRs. Scale bar: 8µm. 
7.24 FT23-50 is binding specifically to HEK
Gpr126  
Flow cytometry with FITC-labeled anti-HA antibody revealed increased FT23-50 binding to HEKGpr126 but 
neither to HEKGpr124 nor to HEKGpr176 cells (Fig. 7.25).  
A B  
Figure 7.25 | FT23-50 is binding to HEKGpr126. A:HA-tagged FT23-50 peptide (2µM) was added to wild-type HEK293T (HEKWT) 
cells or to HEKGPR126 cells, labeled with anti-HA antibody, and subjected to cytofluorimetry. Overexpression of Gpr126 increased 
the binding of FT23-50. B: Binding of HA-tagged FT23-50 to HEKGPR126 cells (right panel, monitored by cytofluorimetry) was 
conspicuously increased over that of wild-type, Gpr176, and Gpr124-overexpressing HEK293T cells.   
7.25 FT23-50 binding to HEK
Gpr126 induces cAMP. 
I next exposed HEK293T and HEKGpr126 cells to FT23-50 (20') and measured cytosolic cAMP. Even the 
lowest tested FT concentration (500 nM) sufficed to significantly raise cAMP levels in HEKGpr126 cells but 
neither in HEKGpr124 nor in HEKGpr176 cells (Fig. 7.26). 




Figure 7.26 | FT23-50 binding to HEKGpr126 induces cAMP.Intracellular cAMP in wild-type HEK293T cells and in Gpr176, 
Gpr124 and Gpr126 overexpressors exposed to FT23-50 (0.5 µM, 20 min). Only HEKGpr126 cells showed a cAMP increase. 
7.26 Is there a direct ligand-receptor interaction of FT with Gpr126? 
Does the effect of FT on cAMP levels derive from a direct ligand-receptor interaction with Gpr126? If so, 
the FT should establish a physical complex with Gpr126. To detect such a complex, I treated naïve 
HEK293T, HEKGpr124 or HEKGpr126 cells with recombinant FT (2µM, 20’) or, with a recombinant GD (2µM, 
20’). I performed immunoprecipitations on cell lysates with anti-V5 antibodies, and probed the blots with 
POM2. FT was detectable only in HEKGpr126 immunoprecipitates and no FT was captured by naïve 
HEK293T or HEKGpr124 cells. Blots probed with POM1 did not reveal any GD binding in any of the cell 
lines. These results confirm that the FT can robustly interact with Gpr126 (Fig. 7.27).  
 
Figure 7.27 | FT co-precipitates with GPR126. HEK293T, 
HEKGPR124 and HEKGPR126 cells were exposed (20 min) to 
recombinant FT, GD (2µM), or PBS, and subjected to 
immunoprecipitation using the anti-V5 antibody, followed 
by Western blotting using POM2, anti-V5 or POM1. Anti-
V5 detected both full-length Gpr126, Gpr124 (denoted as 
GprV5 for both proteins) and the respective C-terminal 
fragments (Gpr126V5-CTF, Gpr124V5-CTF). POM2 
revealed a band corresponding to the FT (lane 3) that co-
precipitated with GPR126. POM1 revealed no bands, 
indicating that GD did not bind. Lanes 1, 2 and 3: HEKGPR126 
cells treated with PBS, GD and FT. Lanes 4, 5 and 6: 
HEKGPR124 cells treated with PBS, GD and FT. Lanes 7, 8 
and 9: HEK293T cells treated with PBS, GD and FT 
Asterisks: immunoglobulin heavy and light chains. 
7.27 A Gpr126-ablated Schwann cell line does not increase cAMP upon FT binding 
To further probe the dependency of the FT-induced cAMP increase on Gpr126, I generated clonal SW10 
cells devoid of endogenous Gpr126. I transfected plasmids expressing Cas9/EGFP and short-guide RNAs 
targeting exon 2 of Gpr126 into SW10 cells and FACS sorted the positive cells. After several weeks of 
THE ROLE OF AXONAL PRION PROTEIN IN MYELIN MAINTENANCE 
51 
 
culturing, I managed to isolate a Gpr126-ablated clone designated SW10∆Gpr126. When treated with FT23-50, 
SW10 (but not SW10∆Gpr126) cells reacted with increased cAMP levels. As a further control, I replaced all 
lysine residues of FT23-50 with alanines. The modified FT23-50	
K→A  peptide was ineffective in binding cells and 
inducing cAMP (Fig. 7.28).  
 
 
Figure 7.28 | A Gpr126-ablated Schwann cell line 
(SW10∆Gpr126) does not increase cAMP upon FT binding. Wild-
type (left) and Gpr126-ablated (right) SW10 cells were exposed to 
FT23-50 (2µM, 20 min). SW10 cells, but not SW10∆Gpr126 cells, 
respond to FT23-50 with a cAMP spike. Moreover, SW10 cells did 
not respond to alanine-substituted FT23-50 (FT23-50	
K→A). 
 
7.28 Reintroduction of GPR126 in SW10∆Gpr126 
I then transfected SW10∆Gpr126 cells with plasmids encoding either of the human Gpr126, Gpr124, Gpr176 
or Gpr56, and treated them with FT23-50 48 h post transfection. Only Gpr126-transfected cells showed a 
cAMP response (Fig. 7.29)  
 
Figure 7.29 | Reintroduction of GPR126 in SW10∆Gpr126. 
Intracellular cAMP responses to FT treatment (2 µM, 20’) in SW10 
and SW10∆Gpr126 cells, as well as SW10∆()*+,-
./()*+,- cells expressing 
V5-tagged human Gpr126 (pCGpr126-V5).  A significant increase 
in cAMP was observed in SW10 cells, whereas SW10∆Gpr126 
showed no change. In contrast, SW10∆()*+,-
./()*+,- cells showed a 
significant cAMP increase, indicative of successful 
complementation. 
 
The magnitude of the cAMP response in Gpr126-transfected cells was similar to that of naïve SW10 cells, 
suggesting that the V5 tag did not affect the function of Gpr126 (Fig. 7.30).  





Figure 7.30 | SW10∆Gpr126 cells plated at a density of 100’000 
cells/well in 6-well plates were transfected with control 
plasmid (pCDNA3) or plasmids encoding various GPCRs 
(Gpr126, 124, 176, and 56) bearing C-terminal V5 tags. Only 
cells transfected with pCGpr126-V5 showed a cAMP 
response to FT23-50. PBS treatment was used for control.   
 
 
7.29 HEKPrP-conditioned medium failed to induce cAMP in SW10∆Gpr126  
Next, I treated SW10 and SW10∆Gpr126 cells with conditioned media from HEKPrP or HEKempty cells. 
HEKPrP-conditioned medium induced cAMP in SW10 cells, but not in SW10∆Gpr126 cells (Fig. 7.31 A). 
Moreover, FT adsorption was reduced in SW10∆Gpr126 cells (Fig. 7.31 B).  
A  B | 
Figure 7.31 | HEKPrP-conditioned medium failed to induce cAMP in SW10∆Gpr126. A: SW10 and SW10∆Gpr126 cells were 
incubated (20 min) with conditioned medium from HEK293T cells transiently transfected with a non-coding vector (HEKempty) or 
with a plasmid encoding murine PrPC (HEKPrP). HEKPrP-conditioned medium induced a robust cAMP spike in SW10, but not 
SW10∆Gpr126 cells. B:  SW10 and SW10∆Gpr126 cells were grown on coverslips for 24h and exposed to recombinant FT (2 µM, 20 
min). Cells were stained with POM2 (detecting FT; red, DAPI-stained nuclei: grey) and antibodies to p75NGFR (yellow). Deletion 
of Gpr126 largely suppressed FT binding. Scale bar: 26 µm. 
7.30 Is the activity of FT specific for Gpr126? 
Is the activity of FT strictly limited to Gpr126, or does it extend to additional adhesion GPCRs? To address 
this question, I administered FT23-50 (2µM, 20’) to HEKGpr126 cells and HEK293(H) cells that are transfected 
with plasmids encoding human Gpr56, Gpr64, Gpr133, or Gpr97. Once again, only Gpr126-expressing 
cells showed a significant cAMP response (Fig. S3D). The magnitude of cAMP response became limiting. 
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A         B  
Figure 7.32 | The activity of FT is limited to Gpr126. A: HEK293(H) cell lines were transfected with plasmids expressing 
different adhesion GPCRs (Gpr: 97, 133, 64, 56), followed by selection of cells expressing the receptor in presence of geneticin. 
GPCR expressing cells and HEKGpr126 cells were then treated with either FT23-50 or FT23-50	
K→A  for control (FT and C, respectively). 
Only cells expressing Gpr126 responded to FT23-50 with a cAMP spike. Interestingly, cells expressing Gpr133 reacted with a 
decrease in cAMP levels. B: HEK293T cells were transfected with increasing amounts of human Gpr126 plasmid (2-5µg/well of 
a 6 well plate). 48h post transfection cells were treated with FT23-50 or PBS as a control. Increasing amount of Gpr126 cDNA did 
not result in amplification of cAMP signal. 
7.31 Does FT lead to a cAMP response in the central nervous system? 
I treated cerebellar granular neuronal cultures from PrnpZH1/ZH1 mice with FT23-50 or FT23-50	
K→A . There was no 
induction of cAMP (Fig. 7.33), as might be expected from the minimal expression of Gpr126 in the brain 
(Zhang et al., 2014). 
 
 
Figure 7.33 | No cAMP burst in cerebellar granular neurons after 
treatment with FT. Primary PrnpZH1/ZH1 cerebellar granule neuron cultures 
were seeded in 6-well plates at a density of 5x105 cells and treated with 
FT23-50, FT23-50	




The FT is released from PrPC by ADAM metalloproteases (Altmeppen et al., 2015). If the cAMP response 
to HEKPrP conditioned media was caused by soluble FT, it should be reduced by inhibiting PrPC cleavage. 
Indeed, after a 24-hr treatment with the metalloprotease inhibitor TAPI-2, HEKPrP-conditioned medium 
contained significantly less FT (Fig. 7.34 B) and, when administered to SW10 cells, possessed a 
significantly reduced cAMP-inducing activity (Fig. 7.34 A).  
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Figure 7.34 | Inhibition of PrPC cleavage reduces cAMP response. A: SW10 cells were exposed to conditioned medium from 
HEK cells that had been transfected with empty vector (HEKempty) or a PrPC expression vector (HEKPrP). HEKPrP were optionally 
treated with 100 µM of the TAPI-2 protease inhibitor for 24h before harvesting the medium. TAPI-2 treatment resulted in reduced 
cAMP induction, suggesting that impaired proteolytic cleavage of the FT from PrPC resulted in decreased signaling. B: 
Quantification of FT released into the medium relative to the total amount of PrPC in lysates by Western blotting. The spent 
medium of HEKPrP cells treated with TAPI-2 contained less FT. 
7.32 Sciatic nerves of PrnpZH1/ZH1 mice show reduced amounts of Egr2 
The transcription factor Egr2 (also called Krox-20) is induced cAMP-dependently at the onset of 
myelination (Monuki et al., 1989; Scherer et al., 1994; Zorick et al., 1999) and controls the expression of 
crucial myelin genes. Conditional ablation studies have implicated Egr2 in myelin maintenance (Decker et 
al., 2006). Egr2 might therefore be an FT effector in vivo. Indeed, I found that Egr2 expression was 
significantly decreased in sciatic nerves of 13-week-old PrnpZH1/ZH1 mice (p<0.05; Fig. 7.35).   
 
Figure 7.35 | Sciatic nerves of PrnpZH1/ZH1 mice show reduced amounts of Egr2. Protein was isolated from wild-type or 
PrnpZH1/ZH1 sciatic nerves (13-week old female mice) and Western blots were probed for EGR2 and actin. Densitometry (right) 
showed reduced Egr2 in PrnpZH1/ZH1 nerves (p=0.028). 
7.33 Luciferase reporter assay for Egr2 
Moreover, I could show that recombinant FT (2 µM, 24h) can activate Egr2-dependent luciferase 
expression in SW10 cells (Fig. 7.36 A). Similarly, Egr2 transcription was significantly upregulated in 
primary Schwann cells treated with recombinant FT (2 µM) for 1h (Fig. 7.36 B).  
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Figure 7.36 | Luciferase reporter assay. A: SW10 and SW10∆Gpr126 cells were transfected with an Egr2-controlled firefly 
luciferase reporter and treated with recombinant FT (2µM) or PBS (24 hrs). Ordinate: luciferase expression normalized to a renilla 
luciferase control (n=3; *: p<0.05; t-test). Luciferase activity was observed only in SW10 cells stimulated with FT but not in 
SW10∆Gpr126 cells.  B: Primary Schwann cells were exposed to recombinant FT (2 µM, 1h) or PBS. Egr2 mRNA expression was 
measured by quantitative RT-PCR and normalized against a panel of housekeeping genes. 
7.34 Akt phosphorylation assay 
The PI3 kinase/Akt pathways are important in the process of proliferation, differentiation and myelination 
of Schwann cells (Ogata et al., 2004). I therefore measured phosphorylated Akt (p-Akt) in SW10∆PrP and 
SW10∆Gpr126cells exposed to recombinant FT (2µM, 20 min; Fig 7.37). Akt phosphorylation increased 
rapidly starting from 5 min post treatment with FT and peaking at 10 min in SW10∆PrP cells, but not in 
SW10∆Gpr126 cells suggesting that FT initiated signaling in Schwann cells via Gpr126.  
 
Figure 7.37 | Akt phosphorylation assay. SW10∆PrP and SW10∆Gpr126 cells were grown in 6-well plates, exposed to recombinant 
FT (≤30 min), and analyzed by Western blotting (left). Densitometry (right) showed increased phospho-AKT/AKT ratio in 
SW10∆PrP cells, but not in SW10∆Gpr126 cells. 
7.35 Do SW10 cells still express myelin proteins? 
To assess the integrity of SW10 cells and their subclones, I checked the expression of peripheral myelin 
genes (Fig. 7.38). 




Figure 7.38 |  Expression of typical Schwann cell markers in SW10 and genetically edited SW10 cell line. SW10, SW10∆PrP 
and SW10∆Gpr126 cells were grown on coverslips and stained with antibodies against Myelin associated glycoprotein (MAG), 
Myelin oligodendrocyte glycoprotein (MOG), glial fibrillary acidic protein (GFAP) and p75 nerve growth factor receptor 
(p75NGFR) (left panel, all green; DAPI-stained nuclei: blue). Cells labeled with secondary antibody alone (2° Ab) were used as 
control to determine unspecific staining. Scale bars: 10µm. Expression in all cell lines was confirmed by western blotting (right 
panel). Lysate from HEK293T wild type cells (HEKWT) was used as control. All proteins except Myelin basic protein (MBP) were 
expressed in SW10 cells and its derivatives.  
7.36 Does FT act by the same mechanism as type-IV Collagen? 
Type-IV collagen (Col4) binds Gpr126 and induces cAMP(Paavola et al., 2014), raising the question 
whether FT and Col4 act by the same mechanism. Sequence alignments identified two regions of similarity 
between the FT (KKRPKPG and QGSPG) and Col4 (GPRGKPG and QGSPG, Fig. 7.39).  
 
Figure 7.39 | Similarities between FT and Col4. Sequence alignment revealed two regions of similarity between the FT and Col4 
(red boxes).. Yellow and green shades represent high and moderate conservation, respectively. 
7.37 Which motif is crucial for signaling? KKRPK or QGSPG? 
This prompted me to test the activity of FT23-50 peptides in which the conserved cationic residues were 
replaced with alanines (KKRPKPG [ AAAPAPG). Treatment of SW10∆PrP cells (2µM, 20’) resulted in 
induction of cAMP by all mutant peptides except those bearing a modified KKRPK sequence (Fig. 7.40).  





Figure 7.40 | Charge replacement in the KKRPK motif abrogates cAMP 
induction. SW10∆PrP cells were treated with synthetic FT23-50 or modified 
version of FT23-50 in which the KKRPK or QGSPG motifs were replaced with 
alanines (2µM, 20'). Alanine substitution of KKRPK (peptide FT23-50	
K→A ), but not 
of QGSPG, abrogated cAMP induction. 
 
 
7.38 Charge replaced murine FT mutants expressed in HEK cells 
Furthermore, I generated murine PrPC mutants containing alanine substitutions in either one of the two 
conserved motifs. After transient transfection, both mutants were highly expressed by HEK293T cells (Fig. 
7.41 A), and cleaved FT was recovered in the medium (Fig. 7.41 B).  
A                             B    
Figure 7.41 | Charge replaced murine FT mutants expressed in HEK cells. A:  Western blot (developed with POM2) of HEK 
293T cells transfected with expression plasmids for wild-type murine PrPC or for PrPC bearing lysine-to-alanine substitutions in 
the KKRPK and QGSPG motifs (lanes 3 and 4, respectively). The mutations did not affect the biogenesis and processing of PrPC 
B: Western blot of the medium collected from the cells shown in panel B. FT fragments bearing the mutations were released into 
the medium similarly to wild-type FT.  
7.39 KKRPK is the functional domain in the HEK cell assay 
When applied to SW10∆PrP cells, the conditioned medium from HEK293T cells expressing PrPC and 
QGSPG-mutated PrPC (HEKPrP∑QGSPG) induced cAMP, whereas medium from cells expressing KKRPK-
mutated PrPC (HEKPrP∑KKRPK) did not (Fig. 7.42).  




Figure 7.42. | KKRPK is the functional domain in the HEK cell assay. SW10∆PrP cells were treated with conditioned medium 
from HEK293T cells transfected with an empty vector (HEKempty), with PrPC (HEKPrP), or with full-length PrPC versions in which 
the QGSPG (HEKPrP∑QGSPG) or KKRPK (HEKPrP∑KKRPK) motifs were substituted (∑) with alanines. The charge neutralization 
within the KKRPK motif abrogated the cAMP induction. 
7.40 Charge replacement in the GPRGKPG motif of Col4 aborgates cAMP induction 
If the sequences conserved between PrPC and Col4 mediate their biological activity, mutation of the 
GPRGKPG motif should abrogate the activity of Col4. I generated 21-mer peptides of Col4 bearing the 
native sequence or an alanine-substituted variant (AAAGAAG). The native peptide (8 µM), but not the 
mutated peptide, induced cAMP in SW10ΔPrP cells (Fig. 7.43). These results suggest that Col4 and PrPC 
activate Gpr126 through a similar mechanism.  
 
 
Figure 7.43 | Charge replacement in the GPRGKPG motif of Col4 
aborgates cAMP induction. SW10∆PrP cells were treated with FT23-50 
(2 µM) or a Col4-derived 21-meric synthetic peptide containing either the 
GPRGKPG domain or its alanine-substituted variant (AAAGAAG; both 
8 µM). Both FT23-50 and the native Col4 peptide, but not the alanine-




7.41 Microstructural comparison between Prnp ablated mice and DhhCre::Gpr126fl/fl mice 
In zebrafish Gpr126 controls myelination but is dispensable for myelin maintenance for at least one month 
(Glenn and Talbot, 2013). In contrast, Prnp ablated mice have no obvious myelination defect but develop 
a late-onset peripheral neuropathy with demyelination, onion bulb formation, loss of axon-Schwann cell 
interactions in Remak bundles, and abnormal Schwann cell cytoplasmic protrusions (Fig. 7.44).  
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Figure 7.44 | Microstructural analysis of sciatic nerves from Prnp ablated mice. A: Transmission electron micrographs from 
14 month old wild-type BL6 and PrnpZH3/ZH3 sciatic nerves (N=3/4 animals). Thinly myelinated axons (arrowhead), loss of axon-
Schwann cell interaction (boxes), abnormal cytoplasmic Schwann cell protrusions (white arrowhead) and initial onion bulb 
formation (asterisk) were observed in PrnpZH3/ZH3 mice. Scale bars: 500 nm. B: Transmission electron micrographs of 14 month-
old PrnpZH1/ZH1 sciatic nerves (ZH1). Black arrowhead: thinly myelinated axons; white arrowhead: abnormal cytoplasmic Schwann 
cell protrusions; boxes: loss of axon-Schwann cell interactions; asterisk: initial onion bulb formation. Scale bar: 2 µm in upper left 
panel; 500 nm in all other panels. 
To test if Gpr126 dysfunction may cause late-onset phenotypes in mice, I examined sciatic nerves from 
one-year-old DhhCre::Gpr126fl/fl mice. In these mice, DhhCre drives Schwann-cell specific ablation of 
Gpr126 from ~E12.5 onwards (Jaegle et al., 2003; Mogha et al., 2013). At one year of age, I noted 
neuropathic traits similar to those of PrPC-deficient mice, including onion bulb formation, Remak bundles 
with reduced numbers of unmyelinated axons, and abnormal cytoplasmic Schwann cell protrusions 
(Bremer et al., 2010b) (Fig. 7.45).  
 
Figure 7.45 |  Microstructural analysis of 
sciatic nerves from DhhCre::Gpr126fl/fl mice. 
Neuropathic phenotype of one-year-old 
DhhCre;Gpr126fl/fl mutant mouse nerves. Left 
panels: toluidine blue-stained sections of 
sciatic nerves from control Gpr126fl/fl 
(phenotypically wild-type) and 
DhhCre::Gpr126fl/fl (Gpr126∆Schwann) mice. 
Gpr126fl/fl nerves were well myelinated (N = 
3/3 animals), whereas Gpr126∆Schwann nerves 
exhibited myelin loss with readily apparent 
onion bulbs (arrowheads) (N = 3/3 animals). 
Right panels: Transmission electron 
micrographs from Gpr126fl/fl and 
Gpr126∆Schwann sciatic nerves. Myelinated axons (“M”) and Remak bundles (“R”) were found in Gpr126fl/fl sciatic nerves (N = 3/3 
animals). Numerous defects were observed in Gpr126∆Schwann sciatic nerves (N = 3/3 animals) including onion bulbs (black 
arrowheads), abnormal cytoplasmic protrusions (white arrows), and loss of axon-Schwann cell interactions (boxes) similarly to 
PrnpZH3/ZH3 mice. Scale bars = 20µm (a-b), 2 µm (c-d). 
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7.42 Proof of principle in another species 
Might the FT activate Gpr126 across species? The experiments involving zebrafish have been performed 
collaboration with the Monk lab in St. Louis, USA. We utilized the hypomorphic gpr126st63 zebrafish 
mutant, which has a point mutation in the signaling domain that reduces Gpr126 trafficking to the 
membrane and protein signaling (Liebscher et al., 2014; Monk et al., 2009). Myelin basic protein (MBP) 
expression is reduced in the posterior lateral line nerve (PLLn) of gpr126st63 zebrafish (Fig. 7.46 A), but 
can be rescued by treatment with exogenous activating small molecules and peptides (Liebscher et al., 
2014; Monk et al., 2009; Petersen et al., 2015). We  applied 20 uM FT23-50 to developing gpr126st63 
zebrafish larvae 50-55h post-fertilization (hpf) and assayed MBP expression in the PLLn at 5 days post-
fertilization (dpf). We found that exogenous FT23-50 sufficed to increase Mbp expression compared to 
DMSO-treated control larvae (Fig. 7.46 B, p < 0.05). To confirm that the effect of FT23-50 on zebrafish 
larvae was due to enhanced Gpr126 signaling, we also treated gpr126st49 larvae with FT23-50. The gpr126st49 
allele contains an early STOP codon prior to the signaling domain and encodes a truncated protein 
incapable of Gs signaling (Monk et al., 2009; Petersen et al., 2015). Mbp was barely detectable in both 
FT23-50 and DMSO-treated mutant gpr126st49 larvae (Fig. 7.46 B) indicating that FT23-50 functions via 
Gpr126 also in teleost fish.  
A B  
 
Figure 7.46 | FT rescues hypomorphic gpr126st63 zebrafish mutant. A: gpr126st63 hypomorphic mutant larvae were treated 
with vehicle (DMSO) or FT23-50 (20 uM) at 50-55 hours post fertilization (hpf) and immunostained at 5 days post fertilization 
(dpf) for myelin basic protein (Mbp, green) labeling maturing Schwann cells. AcTub: acetylated tubulin (red) labeling axons. 
Scale bar = 20 um. The intensity of immunofluorescence was assessed by morphometry (right graphs). FT treatment enhanced 
Mbp immunofluorescence without affecting AcTub. B: Mbp expression was scored in larvae treated with FT23-50 or vehicle 
(DMSO). FT23-50 treatment resulted in a higher proportion of rescued (“some” and “strong”) MBP expression in gpr126st63 
(53% vs. 34%), but not in gpr126st49 larvae (p < 0.05, Fisher’s two-tailed exact test). N.S. = not significant. N ≥ 25 larvae per 
replicate treatment. 
7.43 Can FT increase cAMP levels in mouse scatic nerves and further organs by intravenous injection? 
I next investigated if intravenous administration of synthetic FT23-50 can restore the diminished cAMP levels 
in sciatic nerves of Prnp ablated mouse lines. FT23-50 or FT23-50	
K→A  peptide (600 µg) was administered to 10-
st63 st49 
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16 week old coisogenic C57BL/6J PrnpZH3/ZH3 and wild-type mice (N=8 per group and both groups were 
littermates). Animals were sacrificed 20 minutes post injection. FT23-50, but not FT23-50	
K→A 	, induced a cAMP 
elevation in both PrnpZH3/ZH3 and PrnpZH1/ZH1 sciatic nerves; cAMP reached levels similar to those seen in 
BL6 mice injected with FT23-50	
K→A  (Fig. 7.47A+B). 
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Figure 7.47 | Intrevenous FT injections in mice. A: PrnpZH3/ZH3 and BL6 mice were intravenously exposed to either FT23-50 or 
its non-charged analogue FT23-50	
K→A  (600 µg/animal, 20 min). PrnpZH3/ZH3 sciatic nerves showed a significant cAMP increase after 
injection of FT23-50, but not of  FT23-50	
K→A . FT23-50-treated PrnpZH3/ZH3 sciatic nerves reached cAMP levels similar to those of BL/6 
mice injected with FT23-50	
K→A . Each dot represents an individual animal. B: FT23-50 or FT23-50	
K→A  was intravenously administered to 
PrnpZH1/ZH1 and BL6 mice (600 µg/mouse, 20 min). After FT23-50 injection, cAMP levels in PrnpZH1/ZH1 mice increased to levels 
approaching those of BL6 mice. Each dot represents an individual animal. C+D: cAMP in hearts also spiked in FT23-50 injected 
PrnpZH1/ZH1mice (C) and PrnpZH3/ZH3 mice (D). E+F: FT23-50 or FT23-50	
K→A  was injected intravenously into 10-16-week old PrnpZH1/ZH1 
or BL6 mice (600 µg/animal, 20 minutes). cAMP levels in kidneys (E) and brain (F) showed no significant changes. G: Control 
Gpr126fl/fl (WT) and DhhCre::Gpr126fl/fl mutant (Gpr126∆Schwann) mice were intravenously injected with either FT23-50 or uncharged 
FT23-50 (FT23-50	
K→A ) (600 µg/animal). Sciatic nerves were isolated 20 min post injection. FT23-50 elicited a significant cAMP increase 
in WT mice, but not in Gpr126∆Schwann mice. FT23-50	
K→A 	injection did not alter cAMP levels (N=2). *: p<0.05; **: p<0.01. 
 
FT23-50 induced a cAMP spike also in the heart, which expresses high amounts of Gpr126 (Fig. 7.47 C+D), 
but not in kidney and brain (Fig.7.47 E+F), which do not express Gpr126 (Uhlen et al., 2015). I then 
administered intravenously FT23-50 or FT23-50	
K→A  peptide (600 µg) to DhhCre::Gpr126fl/fl and control Gpr126fl/fl 
mice. FT23-50 induced a robust cAMP spike in Gpr126fl/fl sciatic nerves but not in DhhCre::Gpr126fl/fl nerves 










8.1 Purpose of the study 
At the beginning of my study, I knew from Bremer et al. that axonal prion protein plays an important role 
in myelin maintenance. Their meticulous work has documented a chronic demyelinating polyneuropathy 
CDP in four different Prnp-/- mouse strains. Nuvolone et al. generated a novel Prnp-/- mouse by use of 
TALEN genome editing on a strictly isogenic C57BL/6J background, the ZH3 mouse (Nuvolone et al., 
2016). The ZH3 mouse was devoid of any flanking gene bias and those mice still suffer from chronic 
demyelinating polyneuropathy. The research aim of my study was to identify the molecular mechanism by 
which the cellular prion protein is signaling in myelin maintenance.  
8.2 Summary of results 
First, I could show that the aminoterminal fragment of PrP (aa23-50), the so called flexible tail FT, is able 
to directly bind to the Schwann cell membrane. Binding partner is a protein because surface digestion with 
trypsin abolishes binding of PrP. To what kind of Schwann cell surface protein could PrPC bind? One of 
the most extensive groups of surface receptors are the G protein-coupled receptors, which are able to signal 
via Gs proteins resulting in cAMP elevation. Elevation of cAMP is well described to promote the 
maturation of Schwann cells from pro-myelinating to myelinating stage. In Schwann cell cultures, cAMP 
is artificially increased by adding forskolin, a compound raising intracellular cAMP levels. Therefore, I 
measured cAMP levels in sciatic nerves of Prnp-/- mice, compared to wt and I found a significant decrease 
of cAMP after 10 weeks of age. Next, I could show that treatment of primary Schwann cells with 
recombinant FT was leading to a concentration dependent cAMP increase. The calculated EC50 for FT 
was 860nM. Other domains of PrPC were inefficient in increasing cAMP levels. Because of criticisms that 
recombinant proteins expressed in E. coli could contain heat shock proteins influencing cell signaling, I 
took either cell medium from HEK cells expressing PrP in which FT was present or synthetic peptides not 
expressed by bacteria. Both, HEK cell medium and synthetic peptides resulted in a dose-dependent cAMP 
increase in Schwann cells. Then, I blocked charge cluster 1 and the octapeptide repeats with specific 
monovalent phage-derived Fab fragments. Only pretreatment with the Fab fragment recognizing CC1 
could block cAMP release indicating that the signaling domain of PrPC in myelin maintenance is indeed 
part of amino acid residues 23-50. cAMP levels are often controlled by G protein-coupled receptors 
GPCRs. Signaling via adhesion Gpr126 has been reported to be crucial for radial sorting and myelination 
of the peripheral nervous system in zebrafish and mice. I therefore generated HEK293T cells over-
expressing different candidate GPCRs. I could show strong binding to HEK Gpr126 cells but not to the 
other GPCRs tested. As a functional read-out I treated the HEK cell clones with FT23-50 and only Gpr126 
expressing cells elevated their intracellular cAMP levels. To prove the physical direct interaction of FT23-
50 with Gpr126, I performed immunoprecipitations. Only in cell lysates of HEK Gpr126 cells, I was able 
to pull down FT23-50, indicating that FT23-50 establishes a physical complex with Gpr126. As a further 
control I ablated Gpr126 in the Schwann cell line SW10 by use of CRISPR/Cas9 genome editing. 
SW10DGpr126 did not increase intracellular cAMP levels upon FT23-50 treatment. Then I replaced charge 
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cluster 1 lysine residues by uncharged alanins and the resulting modified peptide did neither bind to 
Schwann cells nor was it efficient in elevating cAMP levels. In order to re-introduce the receptor, I 
transfected SW10DGpr126 Schwann cells with plasmids encoding human Gpr126 and a panel of control 
GPCRs. Only Gpr126-transfected cells showed an elevation of cAMP upon FT23-50 treatment which was 
in the range of wildtype SW10 Schwann cells. Furthermore, SW10DGpr126 Schwann cells did not bind 
FT23-50 on the cell surface. At the onset of myelination, elevation of intracellular cAMP in Schwann cells 
activates transcription factor Egr2 (Krox-20). Egr2 is known to be the orchestrator of myelin gene 
expression. Egr2 in sciatic nerves from Prnp-/- mice were significantly reduced compared to wildtype 
controls and treatment of SW10 cells with FT23-50 significantly upregulated Egr2. The PI3 kinase/Akt 
pathway is important in proliferation and myelination. Therefore, I analyzed pAKT levels in a time course 
experiment where SW10DPrP and SWDGpr126 cells were treated with FT23-50. Only in SW10DPrP but 
not in SWDGpr126 cells pAKT peaked 10 minutes after FT23-50 addition.  
Type-IV collagen (Col4) has been recently reported to be an agonistic ligand of Gpr126 and I wanted to 
investigate if Col4 acts by the same mechanism as FT does. Bioinformatical sequence alignment studies 
revealed two similarity regions between FT (KKRPKPG and QGSPG) and Col4 (GPRGKPG and 
QGSPG). Mutations in the QGSPG domain had no influence on cAMP release but replacement of charged 
amino acids both in FT’s KKRPKPG and Col 4’s GPRGKPG resulted in inefficient cAMP release, 
indicating that Col4 and PrPC activate Gpr126 in a similar manner. 
In Zebrafish, Gpr126 is crucial during development at the onset of myelination (Monk et al., 2009). 
Prnp-/- mice develop and myelinate comparable to wt controls but suffer from defective myelin 
maintenance (Bremer et al., 2010b). DhhCre::Gpr126fl/fl mice activate expression of the Dhh gene at E12.5 
leading to expression of Cre recombinase and subsequent excision of floxed Gpr126 gene. I could show 
that in DhhCre::Gpr126fl/fl mice onion bulb formation, Remak bundles with unmyelinated axons and 
abnormal cytoplasmic Schwann cell protrusions are present in a similar pattern compared to changes in 
Prnp-/- mice. 
Finally, we could show that FT is able to promote myelination across species. Hypomorphic Zebrafish 
larvae gpr126st63 presented enhanced MBP staining of the posterior lateral line nerve (PLLn) after FT 
treatment. This effect was not seen in gpr126st49 larvae which express a truncated Gpr126 incapable of 
Gs-signaling. 
8.3 Importance of the findings 
During more than two decades of prion research, many different probable functions of the prion protein 
have been proposed. Bremer et al. showed in their previous work that four different Prnp deficient mouse 
lines on four different genetic backgrounds (B6, 129, Balb/c and mixed) suffer from a chronic progressive 
polyneuropathy CDP. This finding could lately be confirmed by Nuvolone and Herrmann et al. in a new 
Prnp-/- mouse line ZH3 (Nuvolone et al., 2016). ZH3 mice were generated by use of TALEN genome 
editing on a strictly isogenic C57BL/6J background and are not affected by flanking gene bias. The CDP 
therefore is a very robust and a proven phenotype of the prion protein deficient mouse. In my study, I 
described the molecular mechanism by which axonal PrPC exerts myelin maintenance. The interaction of 
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FT with Gpr126 leading to myelination is to my knowledge the first molecular elucidation of a phenotype 
caused by prion protein deficiency. So far it was known that Gpr126 has a crucial role in myelination of 
peripheral nerves during development (Monk et al., 2011; Petersen et al., 2015). I could show that Gpr126 
is also involved in myelin maintenance. Peripheral neuropathies are very common and debilitating 
disorders whose prevalence is 1.66% in the general population and 6.6% among people older than 60 years 
(Hoffman et al., 2015). Today’s treatment possibilities are extremely limited, therefore the PrP-Gpr126 
interaction could offer novel therapeutic options for this spectrum of diseases. 
8.4 Limitations of the study 
8.4.1 PrPC and Gpr126 knockouts are not similar 
Both Prnp-/- and Gpr126-/- mice suffer from a disease of PNS myelin. However, there is an obvious 
difference between the two knockouts. Prnp-/- mice initially develop completely normal. After 8 weeks of 
age, first ultrastructural changes appear as digestion chambers can be found. Definite clinical signs are 
detected very late in life and start after an age of around 8 month. Prnp-/- mice clearly suffer from a myelin 
maintenance deficiency (Bremer et al., 2010b). On the other hand, Schwann cells in Gpr126-/- mice are 
arrested in promyelinating stage, crucial transcription factors such as Pou3f1, Egr2, myelin protein zero 
MPZ and myelin basic protein MBP are significantly reduced, non-myelinating axons in Remak bundles 
are not observed and radial sorting by Schwann cells is delayed. Therefore Gpr126-/- mice show drastic 
signs of developmental hypomyelination (Monk et al., 2011). This difference raises the question if Gpr126 
and PrPC really act on similar mechanisms in myelination. To circumvent the developmental stage, I 
analyzed DhhCre::Gpr126fl/fl mice, which express Cre recombinase at E12,5 under the desert hedgehog 
promoter leading to a Gpr126 ko after completion of developmental myelination. Sciatic nerves of those 
mice show indeed ultrastructural changes comparable to Prnp-/- mice, suggesting that the two phenotypes 
may share mechanistic similarities. Up to a certain point, I could explain the phenotypic differences with 
the presence of the two described agonistic ligands type-IV collagen and laminin-211, which could 
compensate for missing PrPC during development but not in long-term myelin maintenance. 
8.4.2 Peripheral myelination via Gpr126 is not the only function of PrPC 
PrPC but not Gpr126 is highly expressed in the central nervous system. Therefore, it is very probable that 
PrPC exerts a diffierent function in the CNS. This other function could involve myelination via a different 
G protein-coupled receptor. Although Bremer et al. could not identify any CNS-myelination deficits in 
Prnp-/- mice. 
8.4.3 Does PrPC-Gpr126 signaling play a role in prions disease? 
The prion protein has been intensively studied because it causes the severe and often fatal 
neurodegenerative diseases of the prion’s disease spectrum. All those disorders affect the central nervous 
system and Grp126 is not expressed in the central nervous system as it is published in the GTEx portal 
(gtexportal.org). It is still possible, as mentioned above that Gpr126 is replaced in CNS by another closely 
related adhesion GPCR since adhesion GPCRs often share similar extracellular domains. Gpr126 is 
reported to be highly upregulated in Bergmann glia in the cerebellum which forms the glial scar after 
neuronal loss (Koirala and Corfas, 2010). Therefore, Gpr126 may play a role also in the CNS after neuronal 
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cell loss has already occurred. The strongest point against an implication of FT23-50 in prion disease are 
found in deletion studies. Mice with a truncated amino-terminus can still be infected with prions and are 
perfectly able to propagate them (Fischer et al., 1996).  
8.5 Implications or practical applications of the study 
The so far reported Gpr126 ligands, type-IV collagen (Paavola et al., 2014) and laminin-211(Petersen et 
al., 2015) are not easily useful for therapeutic purposes. Collagen and laminins are ubiquitously found in 
the body, they are sticky, sessile and because of the size prone to fast degradation. FT as a. short peptide 
can serve as a very useful therapeutic agent, as shown while administering systemically to hypomorphic 
Gpr126 mutant zebrafish. Soluble ligands may be beneficial in diseases caused by Gpr126 mutations such 
as idiopathic scoliosis (Kou et al., 2013). It is conceivable that certain hereditary motor-sensory 
neuropathies might benefit from Grp126 activation even if they are caused by defects in other myelin 
proteins. Also, sporadic (Esiri et al., 1997) and hereditary prion diseases (Antoine et al., 1996) frequently 
affect the peripheral nervous system and in some cases the neuropathy was associated with PrPSc deposition 
(Favereaux et al., 2004). But neuropathy is only a side symptom compared to the severe neurodegeneration 
in prion diseases (Neufeld et al., 1992). The treatment of polyneuropathy under these conditions is not 
going to change the fatal course of the disease. A systematic screen of mutations in the PRNP gene among 
108 patients suffering from hereditary motor and sensory neuropathies did not identify a single mutation 
(Koop et al., 2005) leading to the conclusion, that PRNP mutations play a minor role in otherwise highly 
prevalent neuropathies. On the other hand, enhanced PrP-Gpr126 signaling might drive myelination in the 
presence of other myelin disorders. 
8.6 Further research to be done 
Although Gpr126 is not expressed in the central nervous system (CNS), certain mutants of PrPC cause 
myelin pathology in vivo (Radovanovic et al., 2005). This observation raises the question whether 
inappropriate activation of GPCRs may play a role in driving the pathogenesis of prion diseases within the 
CNS. Close relatives of Gpr126 expressed in the CNS with similar extracellular motifs should be screened 
for interaction with PrPC. Furthermore, the course of prion infection in Gpr126 deficient mice should be 
studied. Amino-terminally truncated mice D23-50 should be analyzed for presence of chronic 
demyelinating neuropathy as a proof of principle. Today, it is not yet known or published to what specific 
domain of Gpr126 FT is binding. The process of Gpr126 activation by PrPC is of great importance for the 
understanding of adhesion GPCR function. Does FT bind to one of the amino-terminally exposed cell 
adhesion motifs? Does this lead to a dislocation of the long extracellular aminoterminus which exposes a 
Stachel-like autoactivating domain? Out of a therapeutic interest, a small compound comprising aa 23-50 
of PrPC could serve as a potent pro-myelinating agent, useful to drive myelination in diverse demyelinating 
disorders such as neuropathies, inflammatory or paraneoplastic demyelination or in idiopathic scoliosis. 
Preclinical studies using FT as a therapeutic compound are missing so far.  
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